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 Abstract 
Toxoplasmosis is a widespread parasitic disease caused by Toxoplasma gondii, an obligate 
intracellular protozoa belonging to the phylum Apicomplexa. Toxoplasmosis is a major public 
health problem, infecting one-third of humans worldwide. Due to the fact that no effective 
vaccine is currently available and treatment is based on drugs for which resistance is 
emerging, there is an urgent need to discover novel drug targets that are exploitable for the 
design of new therapeutics against the pathogen. 
A recent proteomic analysis of partially sporulated oocysts of T. gondii showed that oocysts 
have a greater capability of de novo amino acid biosynthesis, shedding light on several stage-
specific proteins whose functional profile is in accord with the oocyst need to resist various 
environmental stresses [1]. Herein, we focused our attention on two enzymes belonging to 
these putative oocyst/sporozoite-specific protein group: the ornithine aminotransferase (OAT) 
and the cystathionine γ-lyase (CGL). OAT is involved in the polyamine metabolism and 
catalyzes the reversible conversion of L-ornithine (L-orn) into glutamate-5-semialdehyde and 
glutamate, while CGL catalyzes the cleavage of L-cystathionine (L-cth) to L-cysteine (L-cys), 
α-ketobutyrate and ammonia in the reverse transsulfuration pathway. Despite the central 
metabolic roles of these enzymes, the functionality of none of them has so far been 
investigated. Herein, a biochemical characterization of OAT and CGL from T. gondii has been 
performed, in order to expand the very limited knowledge about the polyamine and cysteine 
metabolism of the parasite and to explore the possible use of these enzymes as novel drug 
targets against toxoplasmosis. 
Analysis of spectral and kinetic properties of TgOAT revealed that the enzyme is largely 
similar to OATs from other species regarding its general transamination mechanism and 
spectral properties of PLP; however, it does not possess a specific ornithine aminotransferase 
activity, but exhibits both N-acetylornithine (AcOrn) and γ-aminobutyric acid (GABA) 
transaminase activity, highlighting its possible role both in arginine and GABA metabolism in 
vivo. The presence of Val79 in the active site of TgOAT in place of Tyr, as in its human 
counterpart, provides the necessary room to accommodate AcOrn and GABA, resembling the 
active site arrangement of GABA transaminases. Moreover, mutation of Val79 to Tyr resulted 
in a change of substrate preference between GABA, AcOrn and L-orn, suggesting a key role 
of Val79 in defining substrate specificity. 
The purified TgCGL is a functional enzyme which splits L-cth almost exclusively at the CγS 
bond to yield L-cys. This finding likely implies that the reverse transsulfuration pathway is 
operative in the parasite. The enzyme displays only marginal reactivity toward L-cys, which is 
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also a mixed-type inhibitor of TgCGL activity, therefore indicating a tight regulation of 
cysteine intracellular levels in the parasite. Structure-guided homology modelling revealed 
two striking amino acid differences between human and TgCGL active sites (Glu59 and 
Ser340 in human to Ser77 and Asn360 in toxoplasma). Mutation of these two residues to the 
corresponding residues in human revealed their importance in modulating both substrate and 
reaction specificity of the parasitic enzyme. 
Altogether our findings could be considered as a first step toward exploring the possible use 
of TgOAT and TgCGL as an anti-toxoplasmosis drug targets.  
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 Abbreviations/Acronyms 
AcOAT N-acetylornithine aminotransferase 
AcOrn N-acetylornithine 
ADC Arginine decarboxylase 
AdoMet S-adenosylmethionine 
AdoMetDC S-Adenosylmethionine decarboxylase 
BCA β-chloro-L-alanine 
CBL Cystathionine β-lyase 
CBS Cystathionine β-synthase 
CD Circular dichroism 
CGL Cystathionine γ-lyase 
CGS Cystathionine γ-synthase 
CS Cysteine synthase 
dcAdoMet Decarboxylated S-adenosylmethionine 
DSC Differential scanning calorimetry 
DTNB 5,5′-dithiobis-(2-nitrobenzoic acid) 
DTT DL-Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
GABA γ-aminobutyric acid 
GABA-AT γ-aminobutyric acid aminotransferase 
GOX Glutamate oxidase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
ITC Isothermal titration calorimetry 
L-cth L-cystathionine 
L-cys L-cysteine 
LDH lactate dehydrogenase 
L-hcys L- homocysteine 
L-orn L-ornithine 
MBP buffer MOPS, bicine, proline buffer 
NADH β-Nicotinamide adenine di nucleotide 
OAS O-acetylserine 
OAT Ornithine aminotransferase 
ODC Ornithine decarboxylase 
P5C ∆1-pyrroline-5- carboxylate 
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PAG DL-proparglyglycine 
PAO Polyamine oxidase 
PDB Protein Data Bank 
PLP Pyridoxal 5’-phosphate 
PMP Pyridoxamine 5′-phosphate 
POSP Putative oocyst/sporozoite-specific protein 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC Size exclusion chromatography 
SHMT Hydroxymethyltransferase 
SPDS Spermidine synthase 
SPMS Spermine synthase 
SSAT Spermidine/spermine N-acetyltransferase 
Trx Thioredoxin 
UV Ultraviolet 
UV-Vis Ultraviolet-Visible 
wt wild-type 
α-KG α-ketoglutarate 
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The main topic of this Ph.D. thesis is the biochemical characterization of ornithine 
aminotransferase (Chapter 2) and cystathionine γ-lyase (Chapter 3) from Toxoplasma gondii. 
For each enzyme, a brief introduction on the metabolism in which the enzyme is involved and 
known features of the enzyme is given. 
The following sections will give an overview on basic features of Toxoplasma gondii and the 
general mechanism of action of PLP-dependent enzymes. 
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1. Toxoplasma gondii, the causative agent of toxoplasmosis 
Toxoplasma gondii is an obligate intracellular protozoa that belongs to the phylum 
Apicomplexa, precisely to the coccidian subclass. As all the apicomplexa parasites, T. gondii 
possesses a unique organelle called the apicoplast. The apicoplast has a secondary 
endosymbiotic origin and is essential for the survival of the parasite. However, the specific 
functions of this organelle are not fully clarified. Thanks to the genome projects underway for 
T. gondii and Plasmodium falciparum, it is known that the apicoplast is involved in the fatty 
acid biosynthesis and in the synthesis of isopentenyl diphosphate (IPP), a precursor of 
isoprenoids. Moreover, subsequent data showed that the apicoplast of these parasites makes 
iron sulfur complexes and cooperates with the mitochondrion in the synthesis of haem [2]. 
T. gondii has a complex life cycle consisting of different phases of sexual and asexual 
reproduction and uses felidae and warm-blooded vertebrates, i.e., mammals and birds, as final 
or intermediate hosts, respectively. 
There are three infective stages of T. gondii: a rapidly dividing invasive tachyzoite, a slowly 
dividing bradyzoite contained in tissue cysts, and an environmental stage, the sporozoite, 
contained in oocysts [3]. 
Oocysts are produced during the parasite’s sexual cycle that occurs in the intestine of 
definitive host. Oocysts are excreted through cat feces in the environment, where sporulation 
takes place and sporozoites become infective. Upon oral uptake of sporulated oocysts by new 
hosts, sporozoites transform to tachyzoites that actively penetrate all nucleated cells and 
replicate rapidly by repeated endodyogeny. The tachyzoite form causes tissue destruction and 
is therefore responsible for clinical manifestations of the disease. The consequent immune-
response of the host is accompanied by the formation of tissue cysts in which bradyzoites 
multiply slowly by endodyogeny. Tissue cysts are the terminal life-cycle stage in the 
intermediate hosts and are found in the retina, brain, skeletal and heart muscles. Bradyzoites 
could persist inside cysts for the life of the host or they could be released from cysts, 
transform back into tachyzoites that reinvade host cells. If ingested by a definitive host the 
bradyzoites proliferate in epithelial cells of the small intestine. After this asexual 
multiplication, the sexual phase of the life cycle is restored (Figure 1)[4,5]. 
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Figure 1. The complex life cycle of Toxoplasma gondii [6]. 
 
During the developmental transition of these three phases, T. gondii modifies its metabolism, 
and morphology, to adapt to the environmental changes during its life cycle. Regarding the 
energy metabolism, significant differences were found between bradyzoites and tachyzoites. 
Bradyzoites lack a functional TCA (tricarboxylic acid) cycle and respiratory chain. Pyruvate 
kinase and lactate dehydrogenase (LDH) activities are higher in bradyzoites, suggesting that 
lactate production is the major metabolic pathway for energy generation during latency. In 
contrast, tachyzoites use both mitochondrial oxidative phosphorylation and glycolysis to 
generate ATP [7]. The parasite expresses different stage-specific isoforms of some enzymes 
in order to adjust glycolysis fluxes to accommodate proliferation or dormancy. T. gondii 
possesses two isoenzymes of LDH, LDH1 and LDH2, which are respectively tachyzoite- and 
bradyzoite-specific [7]. Moreover, two stage-specific enolase (ENO) have been described. In 
vitro analysis revealed that the tachyzoite-specific ENO2 has a higher specific activity at Vmax 
and a lower denaturation temperature than those of the bradyzoite-specific ENO1. These 
enzymatic properties are in agreement with the metabolic and physiological needs of the 
parasite during differentiation [8]. 
Due to the difficulty in producing and working with oocysts, the sporozoite is the less 
biochemically characterized among the infectious stages of T. gondii. Recent proteomic 
analysis revealed that the metabolic proteins of freshly sporulated sporozoites may be more 
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similar to tachyzoites than to bradyzoites. Indeed, the ENO2 and LDH1 isoforms, that 
predominate in tachyzoites, were detected in oocysts [9]. Moreover, T. gondii oocysts were 
found to possess all the enzymes of both glycolytic and TCA cycle, differing from tachyzoites 
for the expression of isoenzymes of citrate synthase and phosphoenolpyruvate carboxykinase 
[1]. 
It is known that in T. gondii the TCA cycle is not coupled to glycolysis, as the pyruvate 
dehydrogenase complex is specifically localized to the apicoplast and not to the 
mitochondrion [10]. Proteomic data suggested that oocysts generate mitochondrial acetyl-
CoA, necessary to feed the TCA cycle, through the β-oxidation of fatty acids and the 
degradation of branched amino acids. Alternatively, intracellular tachyzoites presumably use 
the enzyme acetyl-CoA synthetase (TGME49_066640), which could produce acetyl-CoA 
from the acetate scavenged from host cell mitochondria, to fuel the TCA cycle [1]. 
Other interesting stage-specific differences were found in amylopectin metabolism and amino 
acid metabolism [1]. T. gondii stores glucose in cytoplasmic granules of amylopectin, found 
to be more abundant in oocysts and bradyzoites than tachizoytes [11]. Oocysts uniquely 
express a 4-α-glucanotransferase, resulting in an increase of amylopectin debranching and 
glucose mobilization. This feature is in agreement with the additional demand of energy 
typical of the oocyst’s sporulation process. 
Regarding amino acid metabolism, oocysts specifically express enzymes with a key role in the 
synthesis of 6 non essential amino acids, i.e., proline, alanine, threonine, cysteine, lysine and 
tyrosine, underlying the capability of oocysts to adapt to the nutrient-poor extracellular 
environment. 
 
2. Toxoplasmosis. 
Toxoplasmosis is a zoonotic disease of medical and veterinary importance with worldwide 
distribution [12]. Seroprevalence varies widely between different countries (from 10 to 80%) 
and often within a given country. As for animals, seroprevalence in human is affected by 
many factors, like climatic and anthropogenic factors, including dietary, social or cultural 
habits, quality of water and sanitation coverage [3, 4]. 
There are essentially two ways of transmission: the vertical and the horizontal transmission. 
The vertical or congenital transmission occurs during pregnancy, when the tachyzoites might 
cross the placenta and infect fetus. Congenital toxoplasmosis may cause abortion, neonatal 
death, or fetal abnormalities [12]. The horizontal transmission of T. gondii may occurs 
through the infection by one of the three life-cycle stages of the parasite, i.e. oocysts, tissue 
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cysts or tachyzoites. Tachyzoites, which are very sensitive to environmental conditions, can 
be transmitted by transplantation of organs or by consumption of unpasteurized milk. In 
general, the majority of horizontal transmissions is caused by ingestion of one of the two 
persistent stages of T. gondii, i.e. tissue cysts in infected meat and oocysts in food or water 
contaminated with cat faece. In particular, sporulated oocysts are a significant source of 
infection for intermediate hosts, as they are very resistant to environmental conditions. They 
are distributed through wind, rain, or harvested feeds and they remain infectious in moist soil 
or sand more than a year. Sporulated oocysts also are highly impermeable and, therefore, are 
also very resistant to disinfectants [5]. 
In immunocompetent individuals, T. gondii infection is asymptomatic in more than 80% of 
cases. On the other hand, toxoplasmosis is always life threatening in immunocompromised 
patients. Clinical manifestations include serious encephalitis, mental status changes, seizures, 
motor deficits, sensory abnormalities, speech abnormalities, hemiparesis and neuropsychiatric 
findings [3, 12]. 
Drug treatment is usually not necessary in asymptomatic hosts, except in children younger 
than 5 years. The most effective treatment for acute cases of toxoplasmosis is the combination 
of pyrimethamine and sulfadiazine, which have a synergic action and target two different 
enzymes along the folate synthesis pathway. In congenital toxoplasmosis, spiramycin is used 
either alone, in order to prevent fetal infection, or combined with sulfadiazine and 
pyrimethamine when there is substantive evidence of fetal infection. Other current therapies 
include the use of clindamycin, atovaquone or azithromycin [12]. 
However, these regimens are inadequate for the treatment of toxoplasmosis for a variety of 
reasons. First of all, they only control the proliferative tachyzoite stage and are unable to 
eliminate the cyst stage of the parasite. Then, the combination of these drug result to be toxic 
and have significant side effects, including hypersensitivity, bone marrow suppression, and 
teratogenic effects. Moreover, these treatments are no selective for toxoplasmosis therapy as 
they were used in the treatment of other apicomplexan disease prior to being repurposed [13]. 
All these motives, in addition to the emerging of parasite drug resistance, suggest that a better 
understanding of unique T. gondii developmental physiology, metabolism, molecular structure 
and virulence is required to facilitate the design of novel inhibitors against parasite. 
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3. Pyridoxal 5’-phosphate enzymes 
Pyridoxal 5’-phosphate (PLP) enzymes are characterized by their involvement in different 
metabolic pathways due to their ability to catalyze a wide repertoire of reactions. Almost all 
PLP-dependent enzymes are associated with biochemical pathways that involve amino acids, 
but they also play key roles in the replenishment of one-carbon units, synthesis and 
degradation of biogenic amines, synthesis of tetrapyrrolic compounds and metabolism of 
amino-sugars [14]. 
Despite the variety of catalyzed transformations by the PLP-enzymes, the mechanisms of 
reaction share several common features. In all PLP-dependent enzymes acting on amino acid 
substrates, the cofactor is covalently bound to the ε-amino group of an active-site lysine 
residue through an imine linkage, forming the so-called internal aldimine. Through 
transimination, the ε-amino group of the lysine residue is exchanged with the α-amino group 
of the amino acid substrate to form the planar external aldimine. Both types of aldimines react 
reversibly with primary amines in a transaldimination reaction, with formation of a geminal 
diamine intermediate, allowing either binding of substrates or release of products (Scheme 1). 
 
 
Scheme 1. Structures of internal aldimine, the geminal diamine and the external aldimine (adapted 
from [15]). 
 
The external aldimine is the common central intermediate for all PLP-catalyzed reactions with 
amino acids. The cleavage of one of the three bonds at Cα gives rise to the quinonoid 
intermediates; the net negative charge arising from the heterolytic cleavage of sigma bonds is 
delocalized by the extensive conjugation of the π-electrons of the pyridine ring of the 
cofactor, that acts as an electron silk [15]. 
An important factor for the reaction specificity is the orientation of the bonds at Cα of the 
substrate moiety in the external aldimine adduct. Dunathan [16] pointed out that the bond in 
the substrate amino acid to be broken by a PLP-dependent enzyme should lie in a plane 
perpendicular to the plane of the cofactor-imine π system. This would minimize the transition 
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state energy by allowing maximum σ-π overlap between the breaking bond and the ring-imine 
π system. It could also provide the geometry closest to that of the planar quinonoid 
intermediate to be formed, thus minimizing molecular motion in the approach to the transition 
state. 
PLP-catalyzed reactions may be classified as reactions proceeding through (Figure 2): 
 Deprotonation: dissociation of the α-hydrogen from the Schiff base leads to a 
quinonoid-carbanionic intermediate that can react in several ways: i) racemisation, 
reprotonation at Cα but without stereospecificity (e.g. alanine racemase); ii) 
transamination, protonation of C4’ of PLP to form a ketimine intermediate that 
undergoes hydrolysis to pyridoxamine phosphate (PMP) and an α-oxo acid (e.g. 
aspartate aminotransferase); or iii) β- (or γ-) elimination and replacement, when a good 
leaving group is present in the β (or γ) position of the amino acid it can be eliminated 
(e.g. tryptophanase and tryptophan synthase). 
 Elimination of CO2: loss of the carboxyl group from external aldimine that most 
commonly leads to the protonation at the original site of decarboxylation followed by 
breakup of the Schiff base (e.g. glutamic acid decarboxylase). 
 Side chain cleavage: Schiff base side chains undergo aldol cleavage. Conversely, a 
side chain can be added by β condensation. The best known enzyme of this group is 
serine hydroxymethyltransferase. 
 
Figure 2. A schematic view of the different reaction types catalyzed by PLP-dependent enzymes 
that act on amino acids [17]. 
 
Due to their common mechanistic features, PLP-dependent enzyme often catalyze different 
chemical reactions, showing ‘catalytic promiscuity’. This feature may have played a 
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fundamental role in divergent evolution and diversification of catalytic properties. Ancestral 
enzymes were probably able to catalyze several reactions, but gene duplication and 
evolutionary pressure may have worked to modify enzymes’ active sites so as to confer 
narrower substrate and reaction specificity [18]. 
Initially, PLP-dependent enzymes have been classified into five distinct structural groups 
[19], which presumably correspond to five independent evolutionary lineages originated very 
early in the evolution (before the three biological kingdoms diverged) from different protein 
ancestors [20]. These families have been named from their more representative enzyme. The 
aspartate aminotransferase family corresponds to fold type I and contains the majority of 
structurally determined PLP-dependent enzymes, consisting of aminotransferases, 
decarboxylases as well as of enzymes that catalyze α,β- and α,γ-eliminations. Its members are 
catalytically active as homodimers, although they may assemble into higher order complexes, 
and their active site lies at on the dimer interface. The tryptophan synthase β-subunit family 
corresponds to the fold type II and differ from those of fold Type I in that the active sites are 
composed entirely of residues from one monomer, with additional regulatory domains. The 
bacterial alanine racemase family corresponds to the fold type III. These enzymes are obligate 
dimers, as each monomer contributes residues to both active sites. In enzymes of the D-amino 
acid aminotransferase family, fold type IV, the cofactor binds with its re side facing the 
protein rather than the active-site pocket as in the fold-type I family, accounting for the 
difference in stereochemistry of the products in the D-amino acid reaction. The enzymes of 
fold type V, e.g. glycogen phosphorylase, are mechanistically distinct in utilizing the cofactor 
phosphate group for catalysis. Subsequently, two more groups were identified by Percudani 
and Perracchi, fold type VI and fold type VII that are represented by D-lysine 5,6-
aminomutase and lysine 2,3-aminomutase respectively, and contains enzymes whose 
structures are unlike all other PLP-dependent enzymes [17]. 
 
4. PLP-dependent enzymes as drug targets. 
A consequence of their widespread metabolic distribution is that a number of these enzymes 
are current drug targets. For example, inhibitors of L-DOPA (L-3,4-dihydroxyphenylalanine) 
decarboxylase are used in the treatment of Parkinson’s disease [21], alanine racemase has 
been identified as antibacterial drug target [22] and inhibitors of γ-aminobutyric acid 
aminotransferase (GABA-AT) are used in the treatment of epilepsy [23]. 
PLP-dependent enzymes are also intimately involved in the metabolic pathways of protozoa 
[24]. However, so far only serine hydroxymethyltransferase (SHMT) and ornithine 
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decarboxylase (ODC) have been targeted to develop clinically useful anti-protozoan drugs. 
Therefore, future studies are required to explore the potential of the other enzymes as anti-
protozoan drug targets. 
Recent analysis for PLP-dependent enzymes suggests three types of emergent drug targets: (1) 
enzymes that are present only in pathogens; (2) enzymes common to both humans and 
pathogens that possess different properties, allowing to discriminate each other; (3) enzymes 
related to a specialized parasitic life style (distinct host cells or particular life cycle phase). 
All these groups of enzymes identify targets that may be of interest in the development and 
design of species-specific therapeutics [24, 25]. 
Regarding the third group of drug targets, a recent proteomic analysis of partially sporulated 
oocysts of T. gondii identified a subset of proteins specifically expressed at the 
oocyst/sporozoite stage of the parasite. Among these putative oocyst/sporozoite-specific 
proteins (POSPs), four PLP-dependent enzymes were found. In particular, the oocyst resulted 
to differ from the tachyzoite for the expression of ornithine aminotransferase (OAT, 
TGME49_069110), an enzyme that takes part in the synthesis of proline and polyamine 
metabolism. The POPS subset also included three enzymes involved in the biosynthesis of 
cysteine: cystathionine β-synthase (CBS, TGME49_059180), cystathionine γ-lyase (CGL, 
TGME49_112930) and cysteine synthase (CS, TGME49_078910). This analysis provided 
proteomic evidence that the capability of de novo amino acid biosynthesis is modulated 
between oocysts and tachyzoites, with oocysts showing a greater persistence than tachyzoites. 
This feature is in accordance with the adaptation of T. gondii oocysts to the nutrient-poor and 
stressing extracellular environment. 
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5. Aims 
This thesis aims to give a detailed biochemical description of two enzymes from T. gondii, the 
ornithine aminotransferase (TgOAT) and the cystathionine γ-lyase (TgCGL), in order to 
expand the very limited knowledge about the polyamine and cysteine metabolism of the 
parasite and to explore the possible use of these enzymes as novel drug targets against 
toxoplasmosis. 
We overexpressed the proteins in E. coli and we isolated the recombinant enzyme as His-
tagged proteins. The kinetic parameters of main and secondary activities were evaluated by 
steady state and pre-steady state analysis. In particular, pre-steady state analysis has been 
performed in collaboration with Prof. Mariarita Bertoldi from University of Verona. 
Moreover, we analyzed oligomeric state, ligand-induced spectral transitions and protein 
stability through an array of biochemical and biophysical techniques, such as UV-Vis and 
fluorescence spectroscopy, circular dichroism spectroscopy, size exclusion chromatography, 
limited proteolysis and differential scanning calorimetry. After a preliminary biochemical 
characterization, mutagenesis studies were performed to identify the key residues in the active 
sites that are responsible for reaction and substrate specificity. 
Collaboration with Dr. Alessandro Paiardini, researcher at Sapienza University of Rome, was 
established in order to perform molecular modelling analysis to understand at a molecular 
level the structure/function relationship, substrate binding and catalytic mechanism of the 
enzymes.  
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Unique substrate specificity of ornithine aminotransferase from 
Toxoplasma gondii 
 
Abstract 
Toxoplasma gondii is a protozoan parasite of medical and veterinary relevance responsible for 
toxoplasmosis in humans. As an efficacious vaccine remains a challenge, chemotherapy is 
still the most effective way to combat the disease. In search for novel druggable targets, 
herein we performed a thorough characterization of the putative PLP-dependent enzyme 
TgOAT. We overexpressed the protein in E. coli and analyzed its molecular and kinetic 
properties by UV-Vis absorbance, fluorescence, and CD spectroscopy, in addition to kinetic 
studies of both the steady state and pre-steady state. TgOAT is largely similar to OATs from 
other species regarding its general transamination mechanism and spectral properties of PLP; 
however, it does not show a specific ornithine aminotransferase activity as its homologs, but 
exhibits both AcOrn and GABA transaminase activity in vitro, suggesting a role in both 
arginine and GABA metabolism in vivo. The presence of Val79 in the active site of TgOAT in 
place of Tyr, as in its human counterpart, provides the necessary room to accommodate 
AcOrn and GABA, resembling the active site arrangement of GABA transaminases. 
Moreover, mutation of Val79 to Tyr results in a change of substrate preference between 
GABA, AcOrn and L-orn, suggesting a key role of Val79 in defining substrate specificity. 
The findings that TgOAT possesses parasite-specific structural features as well as differs in 
substrate specificity from its human homolog make it an attractive target for 
antitoxoplasmosis inhibitor design that can be exploited for chemotherapeutic intervention. 
 
 
 
 
This work was published in the Biochemical Journal (2017) DOI: 10.1042/BCJ20161021 
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1. INTRODUCTION 
 
1.1 Polyamine metabolism 
Polyamines are aliphatic hydrocarbon chains with one or more amine groups. Their positive 
charge at physiological pH enables their interaction with polyanionic molecules such as DNA, 
RNA, phospholipid head groups in cell membrane or cell wall components. Due to their 
variety in terms of molecular structure, valence and prevalence, polyamines undertake 
different roles in the cells such as survival, growth, gene expression, stress response, cell 
differentiation and parasidic activity [26]. 
In Eukariota the biosynthesis of polyamines typically starts with the conversion of arginine to 
ornithine by arginase and the subsequent decarboxylation of ornithine by ODC to form 
putrescine. S-Adenosylmethionine decarboxylase (AdoMetDC) produces decarboxylated S-
adenosylmethionine (dcAdoMet) which, then gives its aminopropyl group to putrescine for 
spermidine and spermine synthesis. Spermidine synthase (SPDS) and spermine synthase 
(SPMS), respectively, catalyse the latter two reactions. An alternative biosynthetic pathway 
that characterized Bacteria and plants is the arginine decarboxylase (ADC) pathway. ADC 
converts arginine into agmatine, which is consequently converted into putrescine by 
agmantinase (Figure 3). 
 
 
 
Figure 3. Reactions and enzymes involved in polyamine metabolism. MTA, methylthioadenosine. 
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The polyamine metabolism is highly divergent among Protozoa. In Trypanosoma brucei and 
Leishmania parasites, putrescine and spermidine are synthesized by ODC, AdoMetDC and 
SPDS. Differently, Trypanosoma cruzi lacks ODC, but does express both AdoMetDC and 
SPDS, implying that once putrescine is transported into the parasite, it can be converted into 
spermidine and spermine by the promiscuous activity of SPDS [27]. Moreover, published data 
have shown that Cryptosporidium parvum has a plant-like pathway that utilizes ADC [28], 
whereas in P. falciparum ODC and AdoMetDC enzymes were components of a bifunctional 
protein [29]. 
Interference with polyamine metabolism has been successfully exploited in the clinical 
treatment of West African sleeping sickness originated by Trypanosoma brucei gambiense by 
using α- difluoromethylornithine (DFMO, Eflornithine), a derivative of ornithine that can 
irreversibly inactivate ODC [30–32]. Furthermore, AdoMetDC, and SPDS have been 
chemically validated as a drug target in the major protozoan parasites and many specific 
irreversible inhibitors have been synthetized [27, 33–36]. These results prompted the idea that 
polyamine metabolism may be an important drug target also in other protozoan parasites 
responsible for global diseases, including T. gondii. 
Recent studies suggest that toxoplasma lacks a forward-directed polyamine biosynthestic 
pathway. Indeed, it is devoid of the activity of two essential enzymes for polyamine 
metabolism such as ODC and ADC, and therefore is auxotrophic for polyamines [37, 38]. T. 
gondii has previously been shown to have a high affinity putrescine transporter, 
demonstrating the ability to scavenge host-derived putrescine [39]. This protozoan synthesizes 
polyamines by a retroconversion pathway from spermidine to spermine and putrescine via 
spermidine/spermine N-acetyltransferase (SSAT) and polyamine oxidase (PAO) [38]. Even if 
polyamine metabolism has not been deeply investigated in T. gondii, it is known that the 
parasite, as Plasmodium, possesses the polyamine-related PLP-enzyme OAT which is 
involved in ornithine homeostasis, control of polyamine levels and synthesis, and mitosis. 
 
1.2 Ornithine aminotransferase 
OAT (E.C. 2.6.1.13) is a strongly conserved enzyme found in almost all eukaryotic 
organisms, from protozoans to humans, and from fungi to higher plants. 
OAT, like every PLP-dependent transaminase, operates via a “ping-pong” mechanism that 
requires two half reactions to complete one catalytic cycle of transamination. In the first part 
of the reaction, L-orn binds to the pyridoxal form of the holo-enzyme (OAT–PLP) with the 
formation of L-glutamate-γ-semialdehyde, which then cyclizes spontaneously to ∆1-pyrroline-
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5- carboxylate (P5C), yielding the pyridoxamine form of the enzyme (OAT–PMP). The 
second half-transamination proceeds through the reaction of α-ketoglutarate (α-KG) with 
OAT–PMP to reform OAT–PLP and release L-glutamate (see Scheme 2). P5C is further 
converted into proline. 
 
 
 
Scheme 2. Overview of the two half-transamination reactions catalysed by OAT. 
 
The human OAT is synthesized as a 49 kDa precursor in the cytosol and it is then imported 
into mitochondria where it reaches the functional conformation upon removal of an N-
terminal mitochondrial targeting sequence (residues 1–25) producing a ~45 kDa mature 
protein [40]. In the PDB databank, six crystal structures of this enzyme, both ligand-free [41] 
and in complex with different substrate analogues [42, 43], are present. These 
crystallographic studies showed that the human enzyme assume an hexameric assembly 
consisting of three homodimers hold together principally by electrostatic interactions. The 
dimer belongs to the fold type I class of PLP-enzymes and it was suggested that it could 
represent the functional unit of the enzyme [41]. In the active site, the PLP cofactor is fixed at 
the interface between subunits and forms an internal aldimine via a Schiff base bond with the 
catalytic Lys. 
Crystal structures of human OAT complexed with inhibitors elucidate the exact mechanism 
for the specific ω-transaminase reaction of the enzyme: the α-carboxylate of L-orn is bound 
by R180 with the non-reacting α-amino group held between the OH groups of Y55 and Y85, 
while R413 interacts with E235 in order to arrange the δ-amino group of L-orn for 
transimination. In particular, the glutamate residue is important for neutralizing the positive 
charge of the R413 through a salt bridge during the first half-reaction, when there is an 
internal PLP
productive binding of 
the second half
half-reaction, this hydrogen bond
α-KG to interact with R413
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determinant of specificity towards L-orn with respect to GABA [44]. Notably, Tyr85 in 
human OAT is replaced by isoleucine in GABA-AT. 
Sequence alignment of OAT from different organisms indicated that both of these tyrosines 
are highly conserved. However Tyr85 (human OAT numbering) is substituted by Val79 in 
TgOAT (Figure 5). Thus, a further aim of this study was to determine the contribution of 
Val79 to the specificity of the TgOAT enzyme by mutating the valine residue to tyrosine. 
 
T. gondii          ----------MATKSDGSASAAAEGGARKTNIEAYRDGLKLKTEEDFFACDRQYVCQNYA 50 
H. sapiens         MFSKLAHLQRFAVLSRGVHSSVA----SATSVATKKTVQGPPTSDDIFEREYKYGAHNYH 56 
P. falciparum      ----------------------------------MDFVKELKSSQDYMNNELTYGAHNYD 26 
P. vivax           ----------------------------------MDFIKELKSSQDYMNNELTYGAHNYD 26 
P. sativum         ----MAATRQVQCLMRRV-----CRGTRTF--AVATQSNASSSSQTIIDKEHQHSAHNYH 49 
S. cerevisiae      ------------------------------------MSEATLSSKQTIEWENKYSAHNYH 24 
B. brevis          ----------------------------------------MSKTNVVIEQTEKFGAHNYH 20 
                                                             . .  :     . .:**  
 
T. gondii          PVPVVISKGKGARVWDINGNEYYDFLAGVSSLSQGHCHPRVIAALCRQAERLTLTLRAFG 110 
H. sapiens         PLPVALERGKGIYLWDVEGRKYFDFLSSYSAVNQGHCHPKIVNALKSQVDKLTLTSRAFY 116 
P. falciparum      PIPVVLKRGKGVFVYDIEDRRYYDFLSAYSSVNQGHCHPDILNAMINQAKKLTICSRAFF 86 
P. vivax           PIPVVLKRGSGVFVYDIEDRRYYDFLSAYSSVNQGHCHPNILNAMINQAKKLTICSRAFF 86 
P. sativum         PLPIVFAHAKGSSVWDPEGNKYIDFLSGYSAVNQGHCHPKILKALHDQADRLTVSSRAFY 109 
S. cerevisiae      PLPVVFHKAKGAHVWDPEGKLYLDFLSAYSAVNQGHCHPHIIKALTEQAQTLTLSSRAFH 84 
B. brevis          PLPIVISKAEGVWVHDPEGNKYLDMLSAYSALNQGHRHPRIIQALKDQADKVTLTSRAFY 80 
                   *:*:.: :..*  : * :.. * *:*:. *::.*** ** :: *:  *.. :*:  ***  
 
T. gondii          NDVTGPACRFMAEMFGYDRVLLMNTGAEAGESALKIARKWAYEVKEIPPDSAKVILCNNN 170 
H. sapiens         NNVLGEYEEYITKLFNYHKVLPMNTGVEAGETACKLARKWGYTVKGIQKYKAKIVFAAGN 176 
P. falciparum      SDSLGVCERYLTNLFGYDKVLMMNTGAEASETAYKLCRKWGYEVKKIPENSAKIIVCNNN 146 
P. vivax           SDSLGVCERYLTTLFGYDKVLMMNTGAEANETAYKMCRKWGYEVKKIPENEAKIIVCNNN 146 
P. sativum         NDRFPVFAEYLTALFGYDMVLPMNTGAEGVETALKLARKWGYEKKKIPNDEALIVSCCGC 169 
S. cerevisiae      NDVYAQFAKFVTEFFGFETVLPMNTGAEAVETALKLARRWGYMKKNIPQDKAIILGAEGN 144 
B. brevis          NDQLGEFYEKLSAVTGKEMILPMNTGAEAVETALKAVRRWAYDVKKVPENQAEIIVCEGN 140 
                   .:      . :: . . . :* ****.*. *:* *  *:*.*  * :   .* :: . .  
 
T. gondii          YWGRTITACSSSTTFD-CYNNFGPFTPGF------ELIDYDDVGALEEALKD---PNVAA 220 
H. sapiens         FWGRTLSAISSSTDPT-SYDGFGPFMPGF------DIIPYNDLPALERALQD---PNVAA 226 
P. falciparum      FSGRTLGCVSASTDKK-CKNNFGPFVPNF------LKVPYDDLEALEKELQD---PNVCA 196 
P. vivax           FSGRTLGCVSASTDRK-CKNNFGPFVPNF------LKVPYDDLEALEVELQD---PNVCA 196 
P. sativum         FNGRTLGVISMSCDNE-ATRGFGPLMPGH------LKVDFGDAEAIERIF-KEKGDRVAA 221 
S. cerevisiae      FHGRTFGAISLSTDYEDSKLHFGPFVPNVASGHSVHKIRYGHAEDFVPILESPEGKNVAA 204 
B. brevis          FHGRTVTVTSFSSAEE-YRRGFGPFTPGF------KIIPYGDIEALKQAI-T---PNTAA 189 
                   : ***.   * *         ***: *.         : :..   :   :      ...* 
 
T. gondii          FFVEPIQGEGGVNVPKPGYLKRAHELCRSKNVLLIVDEIQTGLCRTGRLLAADH--DEVH 278 
H. sapiens         FMVEPIQGEAGVVVPDPGYLMGVRELCTRHQVLFIADEIQTGLARTGRWLAVDY--ENVR 284 
P. falciparum      FIVEPVQGEAGVIVPSDSYFPGVASLCKKYNVLFVADEVQTGLGRTGKLLCTHH--YGVK 254 
P. vivax           FVVEPIQGEAGVILPSDGYFKGVEALCKKYNVLFVADEVQTGLGRTGKLLCTYH--YGVR 254 
P. sativum         FILEPIQGEAGVVIPPDGYLKAVRDLCSKYNVLMIADEIQTGLARTGKMLACDW--EDVR 279 
S. cerevisiae      IILEPIQGEAGIVVPPADYFPKVSALCRKHNVLLIVDEIQTGIGRTGELLCYDHYKAEAK 264 
B. brevis          FMLEPIQGEAGIIIPQEGFLKQAQEVCKANNVLLVSDEIQTGFGRTGKMFASDW--ENVV 247 
                   :.:**:***.*: :*  .::  .  :*   :**:: **:***: ***. :.       .  
 
T. gondii          PDILLLGKSLSAGVVPISAVMGRADVMDVLKPGTHGSTFGGNPLACAVAVEALTVLKDEK 338 
H. sapiens         PDIVLLGKALSGGLYPVSAVLCDDDIMLTIKPGEHGSTYGGNPLGCRVAIAALEVLEEEN 344 
P. falciparum      PDVILLGKALSGGHYPISAILANDDVMLVLKPGEHGSTYGGNPLAAAICVEALKVLINEK 314 
P. vivax           PDVILLGKALSGGHYPISAILANNDVMLVLKPGEHGSTYGGNPLAAAICVESLNVLINEK 314 
P. sativum         PDVVILGKALGGGILPVSAVLADKDVMLCIKPGQHGSTFGGNPLASAVAIAALEVIKEER 339 
S. cerevisiae      PDIVLLGKALSGGVLPVSCVLSSHDIMSCFTPGSHGSTFGGNPLASRVAIAALEVIRDEK 324 
B. brevis          PDMYIMGKALGGGVFPISAVAADKEILSVFEPGSHGSTFGGNPLGCAVAVAAMDVLADEG 307 
                   **: ::**:*..*  *:*.:    :::  : ** ****:*****.. :.: :: *: :*  
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T. gondii          LADRAERLGAQFRDCLRRELYGKVPWIKEIRGRGLLNAVEVDS-D--AIDPNDVVMKLKE 395 
H. sapiens         LAENADKLGIILRNELMK--LP-SDVVTAVRGKGLLNAIVIKETK--DWDAWKVCLRLRD 399 
P. falciparum      LCENADKLGAPFLQNLKEQLKD-SKVVREVRGKGLLCAIEFKN-D--LVNVWDICLKFKE 370 
P. vivax           LSENADRLGGPFLKALKEELKD-SKIVREVRGRGLLCAIEFRN-D--IINVWDICLKFKE 370 
P. sativum         LTERSTKLGGELLGLLHKIQKKHPEHVKEVRGKGLFIGVELNSESLSPVSGFELSEKLKE 399 
S. cerevisiae      LCQRAAQLGSSFIAQLKALQAKSNGIISEVRGMGLLTAIVIDPSKANGKTAWDLCLLMKD 384 
B. brevis          LVQRSLEMGAYFMEKLKE---INNPIIKEIRGRGLFIGLELTTAA------RPYCEKLKE 358 
                   * :.: .:*  :   *          :  :** **: .: .                ::: 
 
T. gondii          NGILSKPTRGRVMRFIPPLVITDEEHRDATTRIIKSFLAVEEERKK-------------- 441 
H. sapiens         NGLLAKPTHGDIIRFAPPLVIKEDELRESIEIINKTILSF-------------------- 439 
P. falciparum      NGLITRSVHDKTVRLTPPLCITKEQLDECTEIIVKTVKFFDDNL---------------- 414 
P. vivax           NGLITRSVHDKTIRLTPPLCITKEQLDECLEIISKTVKYFDDRL---------------- 414 
P. sativum         RGVLAKSTHDTIIRFTPPLCISADEIQQGSKALAEVLEIDLPLLKKTKPKDAVPLAGPSP 459 
S. cerevisiae      HGLLAKPTHDHIIRLAPPLVISEEDLQTGVETIAKCIDLL-------------------- 424 
B. brevis          LGLLCKETHETTIRFAPPLVISKEDLDWAIDRIKQVLHVTE------------------- 399 
                    *:: : .:   :*: *** *. ::       : : .                        
 
T. gondii          ---------- 441 
H. sapiens         ---------- 439 
P. falciparum      ---------- 414 
P. vivax           ---------- 414 
P. sativum         CDRCGRLVYG 469 
S. cerevisiae      ---------- 424 
B. brevis          ---------- 399 
 
Figure 5. Sequence alignment of OAT from different organisms. Black shading indicates the PLP-binding 
lysine. Gray shading indicates Tyr55 (human OAT numbering) which is conserved in OATs. The target residue 
for mutational analysis is highlighted in yellow. The OATs used in this alignment (NCBI accession number) are 
XP_002365604.1, T. gondii ME49; AAA59959.1, H. sapiens; AAA16481.1, P. falciparum; EDL46384.1, P. 
vivax; ABZ10818.1, P. sativum; ONH76070.1, S. cerevisiae; WP_012685950.1, B. brevis. All sequence 
alignments were carried out using the Clustal OMEGA program. 
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2. EXPERIMENTAL 
 
2.1 Materials 
PLP, L-Ornithine, γ-Aminobutyric acid, α-Ketoglutaric acid, Nα-Acetyl-L-ornithine, β-
Chloro-L-alanine, L-Glutamate Oxidase, o-Dianisidine, Peroxidase, L-Lactic Dehydrogenase, 
IPTG, and NADH were purchased from Sigma. 
 
2.2 Protein production 
The complete cDNA of TgOAT (accession number: XM_002365563) in pUC57 vector was 
obtained from Genscript Corporation with a tag of six His at the C-terminal. The gene was 
subcloned into the expression vector pET21a, which was used for the heterologous expression 
of TgOAT in E. coli BL21(DE3) Codon plus cells. After growing cell cultures at 37°C to an 
absorbance at 600 nm of 0.6, expression was induced with 0.5 mM IPTG at 24°C for 20 h. 
Cell were then harvested by centrifugation, resuspended in 20 mM sodium phosphate pH 8, 
300 mM sodium chloride and 1X protease inhibitor EDTA free and lysed by sonication. After 
centrifugation for 30 min at 30,000×g, the supernatant was loaded onto an Ni-affinity column 
equilibrated with 20 mM sodium phosphate at pH 8, 300 mM sodium chloride, and 10 mM 
imidazole. The imidazole concentration was increased to 500 mM in a linear gradient and 
soluble TgOAT eluted between 100 and 200 mM imidazole. The fractions containing TgOAT 
were pooled and, after addition of 100 µM PLP, were concentrated. Elution imidazole and 
unbound PLP were removed by extensive washing with 20 mM sodium phosphate buffer, pH 
8, using Vivaspin concentrators (Sartorius). 
The concentration of monomer was calculated with the extinction coefficient ε280 nm = 40255 
M-1 cm-1 (http://web.expasy.org/protparam/). PLP content in the holo-enzyme was calculated 
by addition of 0.1 M NaOH and using ε388 nm = 6600 M-1 cm-1. The yield from a standard 
purification was approximately 45 mg/L culture. 
Generation of the N-terminally truncated TgOAT variant, without the first 16 residues, was 
performed by PCR (Polymerase chain reaction) amplification using the pET21a-TgOAT 
construct (forward primer 5’-CATATGGCTAGGAAAACGAACATTGAAGCTTACC-3’; 
reverse primer 5’-GGATCCTCAGTGGTGGTGGTGGTGGTGTTTTTTG-3’). The resulting 
DNA fragment was inserted into pET21a at the NdeI/BamHI sites and used to transform the 
E. coli strain BL21(DE3) Codon Plus. 
Generation of V79Y, C179S, C187S, and the double mutant C179S C187S TgOAT was 
carried out by site specific mutagenesis on the N-terminally truncated pET21a-TgOAT 
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construct using the QuikChange® site-directed mutagenesis kit (Agilent Technologies). The 
sequence of the mutated plasmid was verified by DNA sequence analysis. 
Expression and purification of all variants were carried out as described for full length wild-
type TgOAT. The yield from a one-litre purification was approximately 50 mg for the N-
terminally truncated form and 35 mg for other mutants. 
The PLP- and PMP-form of the variants were prepared incubating the enzyme with α-KG and 
L-orn, respectively, for 20 min at room temperature and washing the excess substrates using 
Vivaspin concentrators (Sartorius). The complete conversion in the two forms was then 
monitored by an absorption spectrum. 
The coding sequence for thioredoxin from T. gondii (TgTrx, accession number: 
XM_002370147) was cloned as C-terminal 6xHis-fusion construct in E. coli expression vector 
pET11 using NdeI and BamHI restriction sites. Protein expression was carried out by growing 
freshly transformed E. coli BL21(DE3) cells in LB (Luria-Bertani) medium at 37°C to an OD 
of 0.6 at 600 nm; after induction with 0.5 mM IPTG, cells were grown for 4 hours, harvested 
by centrifugation, resuspended in extraction buffer (20 mM sodium phosphate pH 8, 300 mM 
sodium chloride, and 10 mM imidazole and 1X protease inhibitor EDTA free), and lysed by 
sonication. The cell debris was removed by centrifugation (35,000 ×g for 20min) and the 
supernatant was loaded onto an Ni-affinity column equilibrated with 20 mM sodium 
phosphate at pH 8, 300 mM sodium chloride and 10 mM imidazole. The imidazole 
concentration was increased stepwise, first to 70 mM to remove nonspecifically bounded 
proteins, and then to 500 mM to elute the enzyme. Monomer concentration was determined 
from the calculated extinction coefficient (280nm = 8543 M−1 cm−1; 
http://web.expasy.org/protparam/). The yield from a standard purification was approximately 
20 mg/L culture. 
TgTrx was reduced trough incubation with fresh made DTT solution (1 mM) for 2 h at RT. 
Excess DTT was removed by extensive washing with 20 mM Hepes pH 8, using Vivaspin 
concentrators. To prepare oxidized forms, the proteins were reacted with freshly prepared 
H2O2 (1.1 molar equivalent) for 15 min at room temperature [45]. 
 
2.3 Size exclusion chromatography (SEC) 
The oligomeric state of TgOAT was investigated by size exclusion chromatography using 
Superdex 200 HR 10/300 GL column. Protein elution was performed at a flow of 0.5 ml/min 
in 50 mM sodium phosphate pH 8.5, 150 mM sodium chloride. The calibration curve of the 
column was obtained following the protocol in [46]. 
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2.4 Determination of equilibrium dissociation constant of PLP for TgOAT and V79Y 
variants 
The apo-proteins were obtained by purification from E. coli without addition of PLP. The 
apo-form showed no absorbance between 320 - 500 nm. The holo-enzyme was easily 
reconstituted by the addition of exogenous PLP to the apo-protein. 
The KDPLP was obtained by monitoring the change of intrinsic fluorescence of the apo-protein 
(1µM) in the presence of increasing concentrations of PLP (0.01-10 µM) in 50 mM Bis-Tris 
propane pH 8, at 25 °C. The KDPLP value was calculated using the following eq: 
 = 
 + 
 +		 − + 
 +		 − 4

2
							1 
where  and 
 are the concentrations of TgOAT dimer and PLP respectively, 	 is the 
equilibrium dissociation constant, Y is the fluorescence change at the PLP concentration 
, 
while  is the fluorescence change at saturating PLP concentrations. 
 
2.5 Steady state analysis 
Transaminase activity of TgOAT was detected via (i) the GOX-coupled assay and (ii) the 
ninhydrin assay following the procedures described in [47] and [48], respectively. Briefly, in 
the GOX-assay a reaction mixture containing L-orn, 5 mM α-KG (or 2 mM for V79Y), 50 µM 
PLP, 1 µM TgOAT and 50 mM Hepes pH 8 was incubated at 37 °C for 7 min. After addition 
of 14 mM phosphoric acid followed by incubation at 90°C for 2 minutes to stop the reaction, 
the mixture was centrifuged. 
Then, the mixture was incubated for 90 min at 37 °C in the presence of GOX (0.015 units), 
0.75 mM o-dianisidine, and peroxidase (2.25 units). After addition of sulfuric acid (3.36 mM), 
absorbance was measured at 530 nm. A standard curve was prepared with known 
concentrations of L-glutamate (10-500 µM) supplemented in the reaction mixture, in the 
presence of 50 µM PLP, 5 mM α-KG, and 14 mM phosphoric acid (Appendix, Figure A1). 
The determination of Km and vmax of the substrates was performed varying the concentration 
of one substrate and keeping the other at a constant concentration value. 
In the ninhydrin assay TgOAT was added to an assay reaction mixture containing 50 mM 
Hepes pH 8, pyruvate or oxaloacetate as substrate, 50 mM L-orn, 0.05 mM PLP, and 
incubated for 30 min at 37 °C. Then, 0.6 M HCl and 0.26% (wt/vol) ninhydrin were added to 
stop the reaction and the samples were heated for 5 min at 100 °C. After resuspending the 
pellet in 1.5 ml 99% ethanol, the absorbance was measured at 510 nm. 
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The β-lyase activity of TgOAT towards BCA was detected as described previously [49] by 
monitoring pyruvate formation via NADH-dependent lactate dehydrogenase. 
The Michaelis-Menten equation was used in modelling of data and determination of kinetic 
parameters of TgOAT activity. 
For α-KG, data were fit to a non-hyperbolic curve that considers substrate inhibition: 


=

1 +  ⁄  +  ⁄ 
					2		 
where  is the reaction rate,  is the total enzyme concentration,  is the Michaelis-Menten 
constant,  is the substrate concentration,  is the rate constant, and  is inhibition 
constant. 
The inhibition mode of putrescine and spermidine with respect to L-orn was determined from 
Lineweaver Burk plot. The Ki value was calculated from the secondary plot [50]. 
The kinetic experiments were carried out at least in triplicate, and reported values represent 
means ± S.E.M of two or more independent determinations using different batches of protein 
that were purified separately. Data fitting was carried out with OriginPro8 (OriginLab). 
 
2.6 Pre-steady state analysis 
The reaction of TgOAT-PLP (10 µM) or TgOAT-PMP (10 µM) with various concentrations of 
L-orn (1-100 mM) or α-KG (0.1- 10 mM) were performed in 20 mM sodium phosphate buffer, 
pH 8 at 12°C in 200 µl. In both reactions, 500 absorbance spectra were collected between 
250-550 nm on a J&M Tidas 16256 diode array detector (Molecular Kinetics) using a 
BioLogic SFM300 instrument, with a dead-time of 3.6 ms at a flow rate of 12 mL/s. The 
determination of rate constants was performed by following changes at 416 or 331 nm using 
the non-linear regression equation 
  =	 ! +	∆ #$%&' 				3 
where At is the absorbance at time t, A∞ is the final absorbance, ∆A is the amplitude of the 
phase, kobs is the measured observed rate constant. Global fitting of the absorbance spectra 
were performed using SpecFit, and single wavelength increases or decreases were analyzed 
with Biokine 4.01 (Biologic) software. 
 
2.7 Spectroscopic measurements 
Absorption spectra were collected with a Jasco-V560 UV-Vis spectrophotometer (Easton, 
Maryland, USA), using 20 µM enzyme in a buffer solution containing 50 mM Bis-Tris 
propane pH 8. 
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CD spectra were carried out on a Jasco J-710 spectropolarimeter (Easton, Maryland, USA) at 
25 °C in 20 mM sodium phosphate pH 8. Protein concentration was ~ 30 µM in a cuvette with 
a path length of 1 cm. Spectra were recorded as described in [51]. 
Fluorescence emission spectra were obtained with a Jasco FP8200 spectrofluorometer 
(Easton, Maryland, USA) at a protein concentration varying from 1 to 10 µM in 50 mM Bis-
Tris propane pH 8 at 25 °C upon tryptophans excitation at 280 nm or upon cofactor excitation 
at 331 or 415 nm. Spectra of blanks were subtracted from each spectrum of samples 
containing protein. 
 
2.8 Molecular modelling studies 
The crystal structure of TgOAT in its internal aldimine form (PDB ID code 4ZLV) was used 
to generate the V79Y form of the enzyme, using the “mutagenesis” tool of PyMol [52], 
followed by energy minimization with the BIOPOLYMER package from InsightII (V.2000, 
MSI, Los Angeles), as already described [53]. 
The Dundee PRODRG2 Server [54] was employed to build the energy minimized three-
dimensional structures of the PLP-GABA, PLP-L-Orn and PLP-AcOrn external aldimines 
complexes, which were then docked into the active site of wild-type and V79Y form of 
TgOAT, using the template-based molecular docking approach of Molegro Virtual Docker 
(MVD) software (®CLCbio). The flexible torsions of external aldimines were automatically 
distinguished by MVD, and then checked manually in terms of consistency. A search space of 
15 Å radius was used for docking, which was centred on the active site. The internal aldimine 
form of PLP , as present in 4ZLV, was used as the pharmacophoric group for docking based 
on the template. If an atom of the ligand matched a group definition, a weighted score 
depending on its distance to the centers of the group was given. A grid-based MolDock score 
(resolution 0.30 Å) was utilized as a scoring function, while MolDock SE was used for the 
docking algorithm [55]. A total of 10 runs were used for each ligand. Similar poses (RMSD ≤ 
1.0 Å) were clustered, and the one with the best score was considered to be representative. 
The remaining docking parameters were fixed at default values. Following docking, energy 
optimization of hydrogen bonds was carried out. 
 
2.9 Isothermal titration calorimetry (ITC) 
All ITC experiments were performed on a TA Instrument Nano-ITC (New Castle, Delaware, 
USA). TgTrx binding to TgOAT was evaluated by titrating 2 µl of 2 mM TgTrx solution into 
the reaction cell (200 µL) containing 150 µM protein dissolved in 20 mM sodium phosphate 
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buffer, pH 8 at 25 °C. Prior to each titration Trx and OAT solutions were equilibrated to 25 
°C and degassed. The baseline from a buffer blank titration was subtracted from the raw data. 
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3.2 Spectral properties of recombinant TgOAT 
Native purified holo-TgOAT binds 2 mol of PLP per dimer and shows, in addition to the band 
of aromatic amino acids centred at 278 nm, a major absorption band centred at 416 nm and a 
modest band at about 331 nm, which did not change in pH range 6.0 - 9.0. The 416 nm band is 
characteristic of the ketoenamine form of the internal aldimine between the active site lysine 
286 and PLP, while the 331 nm band can likely be ascribed to a modest amount of the 
enolimine tautomer and/or to traces of PMP bound to the enzyme (Figure 7A) [57–60]. 
Several observations are consistent with the E-PMP presence. First of all, distinct 
preparations of TgOAT show a slight variable ratio of 331/416 nm absorbance (data not 
shown). Moreover, addition of a keto-acid substrate such as α-KG to the enzyme causes a 
modest decrease of 331 nm absorbance and an increase of the 416-nm absorbance band, in 
line with the conversion of E-PMP to E-PLP when a keto-acid substrate is present (Figure 
5A). Thus, the absorbance at 331 nm is mainly due to the PMP form of the cofactor which is 
likely produced by conversion from E. coli of some endogenous amino acid to a keto acid. 
The same behavior has been observed for other transaminases, such as serine–glyoxylate 
aminotransferase from Hyphomicrobium methylovorum [61], and aminotransferase NikK from 
Streptomyces tendae [62]. 
The CD spectrum of holo-TgOAT shows a positive dichroic band at 423 nm and a modest 
signal around 340 nm (Figure 7B). Moreover, the enzyme displays positive dichroic bands 
between 260 and 290 nm, indicating the asymmetry of aromatic amino acids within the active 
site. 
The fluorescence emission spectrum of holo-TgOAT, recorded for excitation at 280 nm, 
exhibits a pronounced peak at 338 associated to direct emission from Trp residues, and a 
much lower intensity emission band around 510 nm that can be attributed to emission from 
PLP, as a result of an energy-transfer process from the excited Trp residues to the 
ketoenamine tautomer of the internal Schiff base [63, 64] (Figure 7C). Direct excitation of the 
holo-enzyme at 331 or 416 nm gives a weak emission at about 384 and 528 nm, respectively 
(data not shown). 
The emission spectrum of apo-TgOAT, upon excitation at 280 nm, displays a peak centered at 
343 nm, with a 5 nm red-shift and a quantum yield ~60% higher compared to the holo-enzyme 
(Figure 7C). The apo-enzyme has no residual activity and does not exhibit absorbance bands 
in the visible region (Figure 7C, inset). Titration of apo-TgOAT with PLP resulted in a 
quenching of intrinsic fluorescence and yielded a KDPLP value for the enzyme of 60 ± 3 nM 
(Figure 7D). 
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Figure 7. Spectroscopic features of TgOAT. (A) Absorption spectra of 20 µM TgOAT alone (solid 
line) and after addition of 1 mM α-KG (dashed line) in 50 mM Bis-Tris propane pH 8. (B) 
Dichroic spectra of TgOAT 30 µM in 20 mM sodium phosphate pH 8. (C) Intrinsic fluorescence 
emission spectra (excitation was at 280 nm) of apo-protein (solid line) and holo-enzyme (dashed 
line) in 50 mM Bis-Tris-propane pH 8.Inset: Absorption spectra of apo-TgOAT just after 
purification (solid line) and holo-TgOAT after saturation with PLP (dashed line) in 20 mM sodium 
phosphate pH 8. (D) Titration of the apo-TgOAT (0.5 µM enzyme dimer) at PLP concentration 
from 0.01 to 10 µM. The fluorescence emission variations were determined after excitation at 280 
nm. 
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3.3 Steady state kinetic studies 
The enzyme showed a temperature optimum for L-orn transamination at 46 °C (Figure 8A) 
and a relatively high thermal stability, with T50 value of ~65 °C (Figure 8B). The rate constant 
of TgOAT at various pH resulted in a maximum activity at pH 8.0. 
 
Figure 8. Kinetic properties of recombinant TgOAT. (A) Measurement of temperature optimum 
for L-orn transamination; TgOAT activity was examined from 10 to 75 °C in 50 mM Hepes buffer, 
pH 8.0. (B) Thermostability of TgOAT measured as residual activity following incubation of the 
enzyme at temperatures from 20 °C to 90°C for 10 min. 
 
The kinetic parameters for transaminase reaction of TgOAT towards L-orn, under saturation 
with α-KG, were compared with those for other organisms and reported in Table 1. TgOAT 
had similar Km value (~ 7 mM) for L-orn to those of the other organisms. However, when the 
kcat of TgOAT (~2 s-1) is compared with that of other OATs, it was significantly lower than 
that reported for the human (~ 74 s-1) and Plasmodium (~ 10 s-1) enzymes [48]. 
 
Table 1. Summary for kinetic parameters for L-orn transamination of TgOAT and OATs  from 
other organisms. 
Organism Specific activity  (µmol mg-1 min-1) kcat (s
-1) Km (mM) kcat/Km  (M-1s-1) 
T  
(°C)  
pH  References 
T.gondiia  2.6 ± 0.5 2.1 ± 0.1 6.9 ± 0.3 304 37 8 Present work 
H.sapiens b 33.5 ± 4.2 73.7 11.7 ± 2.6 6300 37 7.4 [48] 
P.falciparumb 2.0±0.7 (4.6±0.8)d 9.8 1.6 ± 0.1 6100 37 7.4 [48] 
Pisum sativumc 3.6  4.3 15  287 37 8 [65] 
a Kinetic parameters of T. gondii were determined by GOX-assay [47]. 
b
 Kinetic parameters of P. falciparum and human OATs were determined by ninhydrin assay [66]. 
c
 Kinetic parameters of pea OAT were determined with 2-aminobenzaldehyde method [67]. 
d When measured directly after purification. 
 
Notably, when compared to the human enzyme, TgOAT showed a broad substrate specificity 
as in addition to L-orn it also readily accepted GABA and AcOrn as an amino group donor 
(Table 2). Based on kcat/Km values, GABA serves as a better substrate that AcOrn and L-orn 
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for TgOAT (Appendix, Figure A2). While the kcat of the enzyme toward GABA (2.9 s-1) was 
similar to that for L-orn, the Km was ~6-fold higher. Moreover, comparison of relevant kcat/Km 
constants towards AcOrn and L-orn demonstrated that the enzyme had a two-fold preference 
for AcOrn due to a 2.2-fold increase in kcat value. Interestingly, TgOAT can also act on D-orn, 
even if with low catalytic efficiency. 
 
Table 2. Steady-state kinetic parameters of wild-type and V79Y variant of  TgOAT at 37°C 
Substrate Co-substrate kcat (s-1) Km (mM) kcat/Km (M-1s-1) Ki (mM) 
Wild-type      
GABA α-KG 2.91 ± 0.03 1.32 ± 0.02 2204 ± 56 ̶ 
AcOrn α-KG 4.6 ± 0.3 7.4 ± 0.4 622 ± 74 ̶ 
L-orn α-KG 2.1 ± 0.1 6.9 ± 0.3 304 ± 28 ̶ 
D-orn α-KG 0.42 ± 0.05 4.2 ±0.5 1000 ± 23 ̶ 
α-KG L-orn 2.51 ± 0.01 0.31 ± 0.03 8161 ± 815 17 ± 3 
V79Y       
L-orn α-KG 0.21 ± 0.01 3.9 ± 0.1 53 ± 4 ̶ 
GABA α-KG 0.82 ± 0.04 18 ± 4 46 ± 12 ̶ 
AcOrn α-KG 2.5 ± 0.1 496 ± 80 5 ± 1 ̶ 
α-KG L-orn 0.41 ± 0.02 0.056 ± 0.004 7321 ± 880 20 ± 3 
 
Under saturation with L-orn, the amino group acceptor α-KG provided a kcat and Km values of 
2.51 ± 0.01 s-1 and 0.31 ± 0.03 mM, respectively, and showed substrate inhibition with Ki 
value of 17 ± 3 mM. Pyruvate and oxaloacetate do not appear to be adequate amino group 
acceptors. Their relative efficiency compared to α-KG in the reaction with L-orn was 
negligible, scarcely reaching 1% (data not shown). Even though the diamine putrescine and 
the polyamine spermidine were unproductive amino group donors, they were examined as 
inhibitor compounds of the enzyme. 
Spermidine and putrescine act as non-competitive inhibitors with Ki values of 24 ± 4 mM and 
93 ± 5 mM, respectively (Figure 9). 
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Table 3. Steady-state and pre-steady-state kinetic parameters of TgOAT at 12°C 
Transamination half-reaction kinetic parameters 
 Substrate kmax (s-1) Kmapp (mM) kmax/ Km
app
 
(M-1s-1) 
Wild-type     
TgOAT-PLP  L-orn 0.67 ± 0.05
a
 
0.72 ± 0.09b 
7 ± 1a 
7 ± 2b 
96 ± 16a 
103 ± 42b 
TgOAT-PMP  α-KG 103 ± 5 4.5 ± 0.5 22900 ± 3656 
V79Y     
TgOAT-PLP  L-orn --c --c --c 
TgOAT-PMP α-KG 1.23± 0.05 0.027 ± 0.007 45555 ± 13662 
Steady-state kinetic parameters at 12°C 
Substrate Co-substrate kcat (s-1) Km (mM) kcat/Km (M-1s-1) 
Wild-type     
L-orn α-KG 0.7 ± 0.1 15 ± 2 46 ± 13 
α-KG L-orn 1.2 ± 0.2 0.32 ± 0.01 3750 ± 742 
V79Y     
L-orn α-KG 0.08 ± 0.01 16 ± 1 5 ± 1 
α-KG L-orn 0.11 ± 0.02 0.030 ± 0.001 3667 ± 789 
ameasured as 416 nm decrease;  
b
measured as 331 nm increase;  
ckon = 7.3·10-4 ± 3·10-5 s-1mM-1, koff = 0.027 ± 0.002 s-1, Kd = 37 ± 2 mM at 416 nm and kon = 
7.4·10-4 ± 3·10-5 s-1mM-1, koff = 0.032 ± 0.002 s-1, Kd = 43 ± 2 mM at 331 nm. 
 
3.6 Reaction of TgOAT with β-chloro-L-alanine 
As β-elimination is a side reaction common to transaminases, we examined the lyase activity 
of TgOAT with β-chloro-L-alanine (BCA), a substrate with a good β-leaving group. 
We collected spectra as a function of time upon addition of 50 mM BCA to 20 µM TgOAT, 
which caused a decrease of the absorption band at 416 nm and a broad increase in absorbance 
at wavelengths shorter than 350 nm (likely due to the pyruvate product), while the 416 band 
returned to the initial protein signal (Figure 13). The kinetic parameters determined for 
pyruvate production resulted in a kcat of 0.51 ± 0.03 s−1 and a Km of 24 ± 4 mM with a 
catalytic efficiency ~14-fold lower than that for L-orn transamination. Based on the 
knowledge that some aminotransferases become covalently inactivated by product(s) of β-
elimination (syncatalytic inactivation) [68, 69], the residual L-orn transamination activity of 
TgOAT was determined following reaction with BCA. The activity was not reduced, 
indicating that the enzyme was not inactivated as a result of β-lyase reaction. Thus, it is 
unlikely that this reaction would have any biological meaning. 
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Figure 13. Spectral changes after addition of BCA to TgOAT. Absorption spectra of 10 µM 
TgOAT alone (solid line), and after addition of 50 mM BCA (dotted line) immediately (line 1) and 
after 5, 10, 15, 20, 25, and 30 min (line 7). 
 
3.7 V79Y variant 
To assess the contribution of the Val79 in determining TgOAT substrate specificity, we 
produced the TgOAT V79Y variant and analysed its spectroscopic and kinetic properties. The 
V79Y variant binds 2 mol of PLP per dimer, and exhibits absorbance, dichroic, and 
fluorescence features identical to those of TgOAT both alone and in the presence of 
substrates. The KDPLP values for V79Y variant was found to be 270 ± 20 nM, which is 4.5-
fold higher than that of wild-type enzyme. 
The steady-state kinetic parameters of V79Y are listed in Table 2. The V79Y mutation led to 
a small decrease in kcat for GABA (3.7-fold) and for AcOrn (1.8-fold). This loss was 
accompanied by a 15-fold and 70-fold increase in Km for GABA and AcOrn, respectively. By 
contrast, kcat decreased 8-fold for L-orn, although Km was reduced by 1.8-fold. The net result 
was a general decrease of the enzyme catalytic efficiency which is significant toward GABA 
(50-fold) and AcOrn (125-fold) compared to that of L-orn (6-fold). 
In addition, the V79Y mutation led to a 8-fold decrease in kcat for α-KG which is, however, 
countered by a 6-fold decrease in Km, such that kcat/Km is reduced only 1.3-fold. 
Of interest, when tested for β-elimination reaction, the protein variant showed the same 
behaviour as wild-type in terms of both kinetic parameters (kcat 0.89 ± 0.01 s-1, Km 28 ± 2 
mM) and spectroscopic changes, which would indicate that the substitution of Val79 with Tyr 
does not affect β-elimination reaction. 
The half-reactions of V79Y with L-orn and α-KG were analyzed to understand the influence, 
if any, of the mutation with respect to the transamination catalytic mechanism. Rapid-
scanning stopped-flow spectra/analyses of V79Y-PLP in the presence of L-orn or of V79Y-
PMP in the presence of α-KG presented in both cases, a behaviour similar to that of the wild-
type enzyme. The global fitting of the absorbance spectra of both reactions fit to a two
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3.8 Molecular modelling 
In the attempt to rationalize from a structural standpoint the unique substrate preference of 
TgOAT, we modelled the external aldimine of wild-type and the V79Y variant of TgOAT in 
complex with L-orn, AcOrn and GABA by docking means, starting from the crystal structure 
of TgOAT in its internal aldimine form (PDB ID code 4ZLV). 
The predicted binding modes of L-orn in wild-type and V79Y TgOAT are shown in Figures 
16A and 16B, respectively. With the δ-amino group of the substrate covalently bound to PLP, 
the carboxylate group is predicted to form an ion-pair with Arg174, similarly to what 
observed in the crystal structure of human OAT in complex with the substrate analogue 5-
FMOrn (PDB ID code 2OAT) [43]. Another interaction involving the carboxylate moiety is 
represented by a hydrogen bond with the hydroxyl group of Tyr171. Finally, the carboxylate 
is bridged to the phosphate group of PLP through Tyr171 and a water molecule. Another Tyr 
residue of the active site, namely Tyr49, is predicted to interact with the amino group of L-
orn. The presence of a third Tyr in the active site, as observed in the V79Y, is predicted to 
further stabilize L-orn in the active site, through: i) van der Walls interactions between the 
aliphatic tail of L-orn and the aromatic ring of Tyr; ii) a hydrogen bond between the α-amino 
group of L-orn and the hydroxyl group of Tyr. 
Modelling of AcOrn in wild-type and V79Y forms of TgOAT suggests that the N-acetyl group 
of ornithine could be well accommodated in the pocket of the wild-type, but not as well in the 
variant, due to the potential steric hindrance with the Tyr residue (Figures 16C and 16D). 
GABA is predicted to bind to wild-type TgOAT in two equally stable conformations, in which 
its carboxylic group can be oriented toward Arg174 or Arg409, respectively (Figure 16E). In 
the latter case, the presence of the less bulky Val79 in place of a Tyr residue, as observed in 
mammalian OATs (e.g., Tyr85 in human OAT) permits the formation of an additional ion-pair 
interaction between Arg409 and GABA, in addition to the GABA-Arg174 interaction. This is 
also possible thanks to the “switching” of Arg409 between Glu229 and GABA. On the other 
hand, the steric occupancy of a Tyr residue, as observed in V79Y (Figure 16F), greatly limits 
the conformational freedom of GABA and Arg409, potentially resulting in an unfavourable 
entropy loss upon binding. Therefore, as already pointed out [44], Val79 is a major 
determinant of specificity toward GABA versus L-orn. 
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Figure 16. Modelling of the external aldimine of wild-type and the V79Y variant of TgOAT in 
complex with L-orn (A-B), AcOrn (C-D) and GABA (E-F). The external aldimines are shown as 
pink sticks. Residues described in text are labelled in single-letter code. Potential favourable and 
unfavourable interactions are depicted as pink and red dashes, respectively. 
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3.9 Regulation of TgOAT activity by reduced TgTrx 
Recently, OAT from P. falciparum (PfOAT) has been shown to be positive regulated by Trx 
which is able to drastically enhance the activity of the parasitic enzyme. In particular, site-
directed mutagenesis and functional analysis revealed that the interaction between PfOAT and 
Trx is mediated by two cysteine residues, Cys154 and Cys163, that are localized in the 
substrate binding loop [48]. 
Sequence alignment and structural comparison between PfOAT and TgOAT revealed that 
TgOAT also possesses two cysteine residues (Cys179 and Cys187) that are closed enough to 
form a disulfide bond and that are located in the loop involved in the substrate binding 
(Figure 17). 
 
Figure 17. Dimeric structure of TgOAT. PLP is shown in orange, while Cys179 and Cys187 are 
labeled in blue. The substrate binding loop is shown in blue. Molecular graphics images were 
produced using VMD (Visual Molecular Dynamics). 
 
Therefore, we decided to study whether also TgOAT activity could be regulated by TgTrx. 
Recombinant TgTrx was purified as a His-tagged protein to greater than 98% purity as 
confirmed by SDS-PAGE; the size of the protein, calculated with a molecular size marker, 
was about 13 kDa that corresponds well to the molecular mass elucidated from the sequence 
information (12858 Da). 
The effect of different concentration of reduced TgTrx was tested on the transaminase activity 
of TgOAT in the presence of saturating L-orn and α-KG as substrates. Five-min incubation of 
TgOAT with TgTrx in the assay buffer was necessary. We reduced TgTrx and oxidized 
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TgOAT as described in the experimental section. Importantly, oxidation treatment did not 
affect TgOAT activity. 
Interestingly, reduced TgTrx increased the activity of TgOAT in a concentration-dependent 
manner (Figure 18). However, the increase was significantly lower compared to that observed 
in PfOAT for which a 10-fold increase in enzyme activity in the presence of reduced Trx was 
found. Notably, Trx did not cause any change in TgOAT activity when GABA or AcOrn 
where used as substrates (Figure 18). 
 
Figure 18. Representative curve of oxidized TgOAT in the presence of reduced TgTrx. Different 
concentrations of reduced Trx were added to the assay system under substrates saturation. 
 
To analyze the specificity of this putative Trx regulation, we next tested the effect of oxidized 
TgTrx on TgOAT. As shown in figure 19, oxidized TgTrx was able to increase TgOAT 
activity even if to a lesser extent (~ 8 %) compared to reduced TgTrx (~ 25 %). The finding 
that the activity of TgOAT increased in the presence of TgTrx, independently from the redox 
state of the redoxin, raises the question if the in vitro observed Trx regulation of TgOAT 
might be relevant under in vivo physiological condition and if this regulation could be 
independent of the Trx redox state. 
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disulfide reaction, i.e., the typical mechanism of the control exerted by Trx over the activity 
of its target proteins (Figura 21). 
 
 
Figure 21. Representative curve of the activity of TgOAT cysteine mutant in the presence of 
TgTrx. Different concentrations of reduced TgTrx were added to the assay system under saturating 
condition of L-orn and α-KG. 
 
Despite its importance in cellular redox homeostasis, the precise mechanism by which Trx 
recognizes target proteins, especially in the absence of any apparent signature binding 
sequence or motif, remains unknown. Recent studies revealed that the binding of Trx to its 
target does not depend on the redox-state of Trx as Trx recognizes the oxidized form of its 
target proteins with exquisite selectivity, compared with their reduced counterparts [45]. 
Therefore to gain deeper insight into Trx-TgOAT recognition modulating factors, the 
interaction between reduced and oxidized TgTrx and oxidized TgOAT variants was 
investigated also by ITC. Nevertheless, we did not determine the thermodynamic parameters 
of this putative binding because ITC measurements did not show a binding trend. 
Altogether, our findings afford new insight into Trx-TgOAT recognition, which could be 
critical to understanding the enzyme function in normal metabolism. However, further studies 
will be necessary to verify the in vitro and in vivo interaction of the two proteins. 
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4. DISCUSSION 
 
UV-Vis absorbance, fluorescence, and CD analysis indicate that TgOAT is largely similar to 
OATs from other species in term of spectral properties of PLP and mechanism of 
transamination in which the cofactor shuttles between PMP and PLP forms through two 
coupled half-reactions [76, 77]. 
However, the present work shows that TgOAT does not possess a specific ornithine 
aminotransferase activity, as suggested by the published genome of T.gondii 
(http://toxodb.org/toxo/) [78] but exhibits both AcOrn and GABA transaminase activity. 
Indeed, first of all GABA serves as a better substrate than L-orn for TgOAT. This property is 
peculiar to OAT from T. gondii as GABA is an ineffective amino group donor in OATs from 
other organisms such as H. sapiens [44], P. sativum [65], P. falciparum [79], and Bacillus 
brevis [80]. Furthermore, in addition to GABA, TgOAT utilizes AcOrn with higher efficiency 
than L-orn. This is another characteristic feature of TgOAT as no activity is detected for 
human, rat [81], or B. brevis OAT towards AcOrn [80], while P. falciparum OAT [79] and 
pea OAT [65] have a relative conversion rate for AcOrn that is significantly lower than that 
for L-orn. Modeling of L-orn, AcOrn, and GABA in complex with TgOAT provides a clear 
rationale for these unique features. The presence of Val79 of TgOAT in place of Tyr, as 
observed in mammalian homologs, provides the necessary room to accommodate AcOrn, and 
GABA in two equally stable conformations, resembling the active site arrangement of other 
GABA transaminases [23]. Interestingly, a recent work, which identifies a set of 13 amino 
acids in the active site within the ornithine transaminase-like family that could define 
substrate or reaction specificity [82], showed that TgOAT possesses higher sequence 
similarity, with respect to these “active site fingerprints”, to AcOAT than to OAT. OAT is 
highly specific to L-orn, while AcOAT accepts both L-orn and AcOrn [83, 84]. T. gondii OAT 
accepts both L-orn and AcOrn, with even higher efficiency towards AcOrn. 
In light of our findings, TgOAT should more properly be considered as an enzyme with 
potential AcOrn and GABA transaminase function in the parasite cell, rather than an ornithine 
aminotransferase as annotated. The identification of an unanticipated functional GABA shunt 
in T. gondii tachyzoites by metabolite profiling studies [85] supported the possibility that 
TgOAT could have a role as GABA-transaminase in GABA-shunt. Notably, MacRae et al 
[85] suggests the presence in T. gondii of all the genes of GABA shunt, even a gene of 
glutamate transaminase, the second enzyme in the GABA shunt, which has putatively 
annotated as ornithine transaminase. Thus it is likely that TgOAT has a dual AcOrn 
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aminotransferase/GABA aminotransferase activity in vitro playing a role in both arginine and 
GABA metabolism in vivo. In line with this, the genome database for the genus Toxoplasma 
[78] results in both GABA-AT and AcOAT as missing enzymes. Broad specificity is a 
common property of aminotransferases and the extent of these enzymes promiscuity is not 
completely understood in any organism. In this respect, TgOAT resembles the E.coli ArgD 
enzyme, which has dual N-acetylornithine aminotransferase/N-succinyldiaminopimelate 
aminotransferase activity, with a function in both arginine and lysine biosynthesis [83]. 
Due to the possible involvement of TgOAT into two crucial amino acid metabolisms, the 
enzyme could represent a strong candidate for inhibitor design. 
In this regard, we assessed the role of the active site residue Val79 of TgOAT, which is 
replaced by Tyr85 in human OAT, as structural differences between the two enzymes could 
account for inhibitor binding. Tyr85 of human OAT is presumed to be an essential 
determinant in distinguishing OAT from GABA-AT catalysis [44]. Change of Tyr85 to Ile72, 
as found in GABA-AT, converted the human enzyme, which has a 3200-fold preference for L-
orn, to an enzyme with a 5-fold preference for GABA [44]. Exchange toward the human 
residue in TgOAT was accompanied with a general decrease of catalytic efficiency of T. 
gondii enzyme towards all substrates. Nevertheless, it was possible to notice an inversion in 
the substrate preference with L-orn becoming the preferred substrate. The effect of the V79Y 
mutation occurs mainly via Km, showing a clear impact on substrate affinity by the mutation, 
especially towards AcOrn. The presence of Tyr79 in the substituted enzyme provides an 
additional anchor site of L-orn, while partially hampering, by steric hindrance, the binding of 
AcOrn (Figure 16B-D). 
Determination of the pre-steady state kinetic parameters of the half-transamination reactions 
of wild-type and V79Y and their comparison to steady state values measured at the same 
temperature allowed us to reach some interesting considerations. First, while for the wild-type 
protein ketimine formation should be suggested as rate limiting in the L-orn half-reaction, for 
V79Y the rate of ketamine formation does not exhibit saturation and, therefore, the rate 
limiting step of the reaction has changed. On the contrary, the mutation does not affect the 
other half-reaction, from α-KG to L-glutamate, suggesting that for both protein variants 
external aldimine hydrolysis is rate limiting rather than its formation. Thus, pre-steady state 
and steady state kinetic data confirm the hypothesis that mutation impacts L-orn 
binding/processing more than α-KG half transamination. 
In conclusion, our in vitro data demonstrate that TgOAT shows both AcOrn and GABA 
transaminase activities, highlighting its possible alternative role both in arginine and GABA 
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metabolism in vivo. The findings that TgOAT is likely involved into two important amino 
acid metabolisms and is significantly distinct from the well-characterized human enzyme with 
respect to substrate specificity could be considered as a first step towards exploring the 
possible use of TgOAT as an anti-toxoplasmosis drug target. 
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 The transsulfuration enzyme cystathionine γ-lyase is functional 
in Toxoplasma gondii 
 
Abstract 
Sulfur-containing amino acids play a central role in a variety of cellular functions in many 
organisms, therefore investigation of the enzymes involved in their metabolic pathways is of 
great interest. The protozoan parasite T. gondii includes the genes encoding enzymes of the 
reverse transsulfuration pathway, cystathionine β-synthase and CGL (previously annotated as 
cystathionine β-lyase) as well as the gene for the cysteine synthase involved in the de novo 
synthesis of L-cys. However, the functionality of none of these enzymes has so far been 
investigated. 
Herein, TgCGL has been cloned, expressed and physiochemically and enzymatically 
characterized. We showed that TgCGL is a functional enzyme, which specifically catalyzes 
the cleavage at the CγS bond of cystathionine. This finding likely implies that the reverse 
transsulfuration pathway is operative in the parasite. The enzyme displays only marginal 
reactivity toward L-cysteine, which is also a mixed-type inhibitor of TgCGL activity, 
therefore indicating a tight regulation of cysteine intracellular levels in the parasite. 
Moreover, by employing structure-guided homology modelling we identified two main 
differences between the active sites of human and parasite enzymes: Glu59 and Ser340 in 
human to Ser77 and Asn360 in toxoplasma. Mutation of Asn360 to Ser revealed the 
importance of this residue in modulating the specificity of the parasitic enzyme for the 
catalysis of α,γ- versus α,β-elimination, suggesting a role in enforcing the appropriate binding 
conformation of the pseudo-symmetric L-cth substrate within the active site. Replacement of 
Ser77 by Glu completely abolished activity toward L-cth. Due to the presence of Tyr71, 
which is missing in human CGL, the side-chain of Glu77 is forced to occupy the same cleft of 
L-cth, likely interfering with its binding. 
Our data, indicating that TgCGL exhibits notable differences with the human counterpart, 
might have far-reaching implications for the use of TgCGL as anti-toxoplasmosis drug target. 
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1. INTRODUCTION 
 
1.1 Sulfur-containing amino acids metabolism 
Sulfur-containing amino acids cysteine and methionine and their metabolic intermediates play 
essential roles in virtually all living organisms from bacteria to higher eukaryotes. 
Due to the unique properties of sulfur and thiol, cysteine plays a relevant role in stability, 
structure, catalytic activity, and regulation of numerous proteins. Cysteine also takes part in 
the synthesis of glutathione, which plays a key role in protection from oxidative stress. 
Methionine is also a significance constituent of proteins and its oxidation and reduction in a 
protein are involved in the regulation of enzymatic activities. Moreover, methionine plays 
various roles through its activated intermediate S-adenosylmethionine (AdoMet) [86]. Despite 
the biological significance of the ubiquitous sulfur-containing amino acids, the distribution of 
their metabolic pathways is extremely diverse among organisms. Indeed, genome-wide and 
functional analyses of enzymes involved in the sulfur metabolic pathways have showed 
notable heterogeneity among protozoan parasites and between parasites and their mammalian 
hosts. Thus, the enzymes involved in sulfur-containing amino acids metabolic pathways are 
interesting drug targets. 
Bacteria, fungi and plants possess the forward transsulfuration pathway, which is involved in 
the formation of methionine from cysteine. The enzymes implicated in these reactions are the 
cystathionine γ-synthase (CGS, EC 2.5.1.48), which converts cysteine and O-
succinylhomoserine in cystathionine and succinate, and cystathionine β-lyase (CBL EC 
4.4.1.8), which catalyzes an α,β-elimination of cystathionine to produce homocysteine and 
pyruvate. These organisms are also capable of de novo production of cysteine by sulfur 
assimilation. This pathway is catalyzed by two steps, initiated by serine acetyltransferase 
(SAT, EC 2.3.1.30) to form O-acetylserine (OAS) from L-serine and acetyl-coenzyme A. 
Subsequently, OAS reacts with sulfide to produce cysteine in an alanyl-transfer reaction 
catalyzed by cysteine synthase (CS, OAS thiolyase, EC 2.5.1.47) (Figure 22). 
In mammals, cysteine is synthesized from methionine via cystathionine by the so-called 
reverse transsulfuration pathway. This pathway is considered to be the unique route for 
cysteine synthesis in vertebrates and involves two PLP-dependent enzymes, cystathionine β-
synthase (CBS, EC 4.2.1.22), which synthesizes cystathionine from homocysteine and serine 
via a β-replacement reaction, and CGL (EC 4.4.1.1), which catalyzes the hydrolysis of 
cystathionine via an α,γ- elimination reaction, to yield cysteine, α-ketobutyrate, and ammonia 
(Figure 22) [87]. 
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Figure 22. Sulfur-containing amino acid metabolism. CBS, cystathionine β-synthase; CBL, 
cystathionine β-lyase; CGS, cystathionine γ-synthase; CGL, cystathionine γ-lyase; CS, cysteine 
synthase; SAT, serine acetyltransferase; OSHS, O-succinylhomoserine. 
 
Parasitic protozoa are characterized by remarkable differences in the above described 
transsulfuration pathways. For example, it has been demonstrated that Entamoeba histolytica 
lacks genes encoding enzymes of the transsulfuration pathway in both directions [88], Giardia 
duodenalis, Trichomonas vaginalis, P. falciparum and C. parvum lack both CBS and CGL of 
the reverse transsulfuration pathway [86, 89, 90]. In T. cruzi the enzymes CBS, CS and CGL 
have been identified and characterized [91, 92], thus indicating that in this pathogen cysteine 
could be produced by the de novo synthesis processes as well as by the reverse 
transsulfuration pathway. 
The presence of genes for the enzymes CBS (TGME49_059180), CGL (TGME49_112930), 
and CS (TGME49_078910) in the genome of the intracellular protozoan parasite T. gondii 
raises the possibility that this parasite possesses both the reverse transsulfuration and the 
assimilatory cysteine biosynthetic pathways. However, although sequence analysis is an 
invaluable tool for unraveling the function of a gene product, further enzymatic and 
biochemical characterization of the encoded protein is necessary to unequivocally identify its 
function and properties. Moreover, since the main transsulfuration enzymes belong to the 
same so-called fold-type I of PLP-dependent enzymes [93], gene function prediction and gene 
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nomenclature assignment based only on phylogenetics and sequence alignment are often 
complicated [94]. 
 
1.2 Cystathionine γ-lyase 
CGL catalyzes the γ-cleavage of cystathionine to yield cysteine, α-ketobutyrate, and 
ammonia. This enzyme is present in actinobacteria, fungi, and mammals. CGLs are 
homotetramers and carry one PLP cofactor per monomer covalently bound through a Schiff 
base to an active-site lysine. 
A molecular mechanism was deduced on the basis of the structural similarity to the E. coli 
CBL active site (Scheme 3). In the first step, substrate binds to the active-site PLP cofactor by 
formation of a Schiff base. α-Proton abstraction by the active-site lysine residue, followed by 
reprotonation at C4’ leads to the reversible formation of a ketamine intermediate. This species 
subsequently undergoes β-proton abstraction by the same lysine which is responsible for the 
proton transfer from Cα to C4’ of the cofactor and the subsequent deprotonation of Cβ to 
initiate the γ-cleavage [95]. 
 
Scheme 3. Reaction scheme for CGL up to the point of the release of cysteine [95]. 
 
Human CGL displays an interesting substrate specificity with clear preference of C–S over S–
S bond breakage: L-cys and L-cystine are converted orders of magnitudes more slowly than 
the natural substrate L-cth. The yeast enzyme attacks the C–β–S bond of L-cystine or L-cys. 
In humans, L-cth is split almost exclusively in a CGL-specific manner, whereas the yeast 
enzyme harbors pronounced CBL activity. A CGL enzyme from Lactococcus lactis was 
reported to consist of at least six identical subunits and have a broad substrate specificity and 
relatively low specific activity toward L-cth compared to bacterial CGL. The reaction 
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specificity seems context-dependent, such that the reaction catalyzed in vivo depends on the 
substrate supplied. 
Despite the high degree of conservation of CGL among different organisms, inspection of 
human and T. gondii active sites overlays by structure-guided homology modelling identified 
two striking amino acid differences (Glu59 and Ser340 in human to Ser77 and Asn360 in 
toxoplasma). 
In particular, sequence alignment of CGL from different organisms resulted in the presence of 
conserved acidic Glu or Asp residue at position 59 and Ser residue at position 340 in all 
organisms except protozoa, e.g. trypanosomes in general, Lehismania major, and T. gondii, in 
which a serine and an asparagine residues respectively were found (Figure 23).  
Herein, we have cloned, expressed in E. coli, and characterized the putative CGL from T. 
gondii (TgCGL) with the aim to expand the very limited knowledge about the transsulfuration 
and cysteine biosynthesis routes in this pathogen and to explore the potential of TgCGL as 
anti-toxoplasmosis drug target. 
Furthermore, in order to in-depth understand the structure–function relationships that control 
substrate and reaction specificity, which is a necessary step to develop novel therapeutics, we 
substituted the non-conserved serine and asparagine residues of TgCGL to glutamate and 
serine residues respectively, as found in human enzyme, and we examined their influence on 
enzyme function. 
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T.gondii          MASKQNDKDGAVRRDASFECGVKAGDWLPGFTPREETVYVHGGVEPDP-LTGAILPPIYQ 59 
L.major           MSSQ---------QHLVSDFTAGSGSWLPQSQ-GFDTLQVHAGVRPDP-VTGAILTPIYQ 49 
T.cruzi           MSSQ---------KHLVSDFTEGSGSWQDQTY-GFDTVLVHGGVKPDP-VTGAVLTPVYQ 49 
T.grayi           MSGA---------QHLFADFSEGSGSWQPQAQ-GFETLLVHGGVKPDP-VTGAILTPVYQ 49 
H.Sapiens         ----------------MQEKDASSQGFLPHFQ-HFATQAIHVGQDPEQWTSRAVVPPISL 43 
S.Cerevisiae      ----------------MTL---------QESD-KFATKAIHAGEHVD--VHGSVIEPISL 32 
C.albicans        ----------------MTI-------ESSTNY-SFGTKAIHAGAPLDP-STGAVIEPISL 35 
                                                      *  :* *   :     ::: *:   
 
T.gondii          NTTFVQESVENYLSKGFSYSRTSNPTVLSLEKKIAEIEGGFGACCFATGMAATVTIFSAF 119 
L.major           STTFVQESINSYQAKGYSYTRSANPTVAVLEQKLCALENGSYCTVYNTGMAATTTAISSF 109 
T.cruzi           STTFVQESIGKYQSKGYSYTRCANPTVSVLERKLCAIENGDYATVYSTGMSATTTAISSF 109 
T.grayi           STTFVQESIERYQAKGYSYTRSANPTVSALEEKLCAIEHGEYATVYSTGMSATTTAISSF 109 
H.Sapiens         STTFKQGAPGQ-HSG-FEYSRSGNPTRNCLEKAVAALDGAKYCLAFASGLAATVTITH-L 100 
S.Cerevisiae      STTFKQSSPAN-PIGTYEYSRSQNPNRENLERAVAALENAQYGLAFSSGSATTATILQ-S 90 
C.albicans        STTFAQSEPSK-PLGIYEYSRSSNPNRDNFEIAVAALESAKYAIALSSGSATTALVIQ-S 93 
                   *** *          :.*:*  **.   :*  :. :: .       :* ::*        
 
T.gondii          LAPGDHCLVTNCSYGGTNRCARLHFSKYNIDFEFIDFRDPTNVEKAIRPQTKVVFSESPC 179 
L.major           MNAGDHAILTNCCYGGTNRACRVFFSRLGMEFTFVDMRDPQNVIDSIKPNTKLVISETPA 169 
T.cruzi           MSAGDHAIITDCSYGGTNRACRVFFPRFGMEFTFVDMRDLKNVEAAIKPNTKLVFSETPA 169 
T.grayi           MSAGDHAIVTECSYGGTNRACRVFFTRLGMSFTFVDMRDVKNVEAAIKPNTKLVISESPA 169 
H.Sapiens         LKAGDQIICMDDVYGGTNRYFRQVASEFGLKISFVDCSKIKLLEAAITPETKLVWIETPT 160 
S.Cerevisiae      LPQGSHAVSIGDVYGGTHRYFTKVANAHGVETSFTNDLLN-DLPQLIKENTKLVWIETPT 149 
C.albicans        LPINSHIVSSGDVYGGTHRYFTKVANTHGVEAQFVGNLVE-DLQGALRENTRLVWLETPS 152 
                  :  ... :     ****:*         .:.  * .      :   :  :*::*  *:*  
 
T.gondii          NPTLYLADIEAISQICKEK------KVLHVCDSTFATPYMMRPLDLGADIVVQSTTKYYD 233 
L.major           NPTLILIDVAAVSKICKER------GIVHMCDNTFATAYIMRPLDHGADVTLISTTKYVD 223 
T.cruzi           NPTLTLTDLTELSKLCKAK------GLIHVCDNTFATAFIMRPLDLGADVTLISTTKFVD 223 
T.grayi           NPTLTLTDIDALSSLCKAK------GIIHMCDNTFATAFIMRPLDHGADVTLISTTKFVD 223 
H.Sapiens         NPTQKVIDIEGCAHIVHKH-----GDIILVVDNTFMSPYFQRPLALGADISMYSATKYMN 215 
S.Cerevisiae      NPTLKVTDIQKVADLIKKHA--AGQDVILVVDNTFLSPYISNPLNFGADIVVHSATKYIN 207 
C.albicans        NPTLQVTDIAKVKSILVDHEAKTGNKVLLAVDNTFLSPYLSNPLTHGADVVVHSVTKYIN 212 
                  **:  : *:         :       ::   *.** : :: .**  ***: : *.**: : 
 
T.gondii          GHNCTLGGAVISSTKEIHDKVFFLRNVMGNIMSAQTAFYTLLTLKTLPIRVEKQSANAQK 293 
L.major           GHDMTVGGALVTNSKELDAKVRLTQNILGNVMSPQVAFLQLQTVKTMSLRVTKQSHNAQK 283 
T.cruzi           GHNMTVGGALVTKRKDLDEKVRLTQNILGNAMSPFVAYLQLQTVKTMSLRVAKQSENAQK 283 
T.grayi           GHNMTVGGALVTKSKELDGKVRLTQNILGNCMSPFVAFLQLQTVKTMSLRISRQSENAQK 283 
H.Sapiens         GHSDVVMGLVSVNCESLHNRLRFLQNSLGAVPSPIDCYLCNRGLKTLHVRMEKHFKNGMA 275 
S.Cerevisiae      GHSDVVLGVLATNNKPLYERLQFLQNAIGAIPSPFDAWLTHRGLKTLHLRVRQAALSANK 267 
C.albicans        GHSDVVMGVLATNDSQLHERFRFLQNAIGSIPSPFDSWLAHRGLKTLHLRVRQASNSAQR 272 
                  *:. .: * :  . . :  :. : :* :*   *   .:     :**: :*: :   ..   
 
T.gondii          IAEFLSKH-HKVEHVIYPGIPSFPQKELALKQHK-NVHGGMLAFEVKGGTEAGIRMMNHV 351 
L.major           IAEFLETH-RAVDRVVYPGLASHPQKELADRQHRNNLHGGMLWFEVKGGTAAGRRLMDTV 342 
T.cruzi           VAEFLETH-PAVEKVMYPGLKSFPQKALADRQHLNNNHGGMLWFEVKGGTAAGRKLMDTV 342 
T.grayi           VAEFLETH-PAVERVMYPGLKSFPQKALADRQHANNLHGGMLWFEVRGGTAAGRRLMDTV 342 
H.Sapiens         VAQFLESN-PWVEKVIYPGLPSHPQHELVKRQCTG--CTGMVTFYIKGTLQHAEIFL-KN 331 
S.Cerevisiae      IAEFLAADKENVVAVNYPGLKTHPNYDVVLKQHRDALGGGMISFRIKGGAEAASKFA-SS 326 
C.albicans        IAEYLSQH-SAVLKVNYPGLKSHRNHDVVLRQQRDGLGGGMISFRIAGGAKGAAVFT-SS 330 
                  :*.:*  .   *  * ***: :. :  :. :*       **: * : *    .  :     
 
T.gondii          PRPWSLCENLGACESIITCPAVFTHANMLREDRLKVGITDGFIRVSVGIEDVNDLIDGLD 411 
L.major           PRPWSLCENLGASESIITCPSVMTHANMTSEDRMKVGITDGFVRVSCGIEDVDDLIAALK 402 
T.cruzi           QRPWSLCENLGAAESIITCPSVMTHANMTKEDRLKVGITDGFVRVSCGIEEAKDLITALK 402 
T.grayi           QRPWSLCENLGATESIITCPSVMTHANMTTEDRMKVGITDGFVRVSCGIEDAADLISALK 402 
H.Sapiens         LKLFTLAESLGGFESLAELPAIMTHASVLKNDRDVLGISDTLIRLSVGLEDEEDLLEDLD 391 
S.Cerevisiae      TRLFTLAESLGGIESLLEVPAVMTHGGIPKEAREASGVFDDLVRISVGIEDTDDLLEDIK 386 
C.albicans        TKLFTLAESLGGIESLIEVPAIMTHGGIPKEEREANGVYDDLVRVSVGIEDTEDLLKDIE 390 
                   : ::*.*.**. **:   *:::**..:  . *   *: * ::*:* *:*:  **:  :. 
 
T.gondii          YALSKA-------- 417 
L.major           VAMDALV------- 409 
T.cruzi           TALDAL-------- 408 
T.grayi           AALDALGK------ 410 
H.Sapiens         QALKAAHPPSGSHS 405 
S.Cerevisiae      QALKQATN------ 394 
C.albicans        QALQKAASV----- 399 
                   *:.           
 
Figure 23. Sequence alignment of CGL from different organisms. Black shading indicates the PLP-binding lysine and the 
tyrosine involved in aromatic stacking interaction with PLP pyridine ring. Gray shading indicates Glu339 (hCGL 
numbering) which is conserved in 100% CGLs. The target residue for mutational analysis is highlighted in yellow. The 
CGLs used in this alignment (NCBI accession number) are XP_002364505.1, T. gondii ME49; XP_003722717.1, L. major; 
EKG03141.1, T. cruzi; XP_009313447.1, T. grayi; NP_666065.1, Homo sapiens; NP_009390.1, S. cerevisiae; 
XP_716241.1, Candida albicans. All sequence alignments were carried out using the Clustal OMEGA program. 
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2. EXPERIMENTAL PROCEDURES 
 
2.1 Protein production 
The complete cDNA of TgCGL (accession number: XM_002364464) in pMA-T vector was 
obtained from Invitrogen Corporation with a tag of six His at the N-terminal. The gene was 
cloned into the vector pET21a for the expression in E. coli Rosetta (DE3) cells. Cell cultures 
were grown at 37°C to an absorbance at 600 nm of 0.6. The expression of TgCGL was 
induced with 0.5 mM IPTG at 24°C for 20 h. Vitamin B6 (0.1 g/L) was added to the cell 
culture during induction in order to favour the proper protein folding and increase the protein 
stability. Cells were isolated by centrifugation, resuspended in 20 mM sodium phosphate pH 
8, 150 mM NaCl buffer containing 1X protease inhibitor EDTA free, and lysed by sonication. 
Cell debris were removed by centrifugation (30000 xg for 15 min) and 1% streptomycin was 
added to supernatant to remove nucleic acid contamination. After centrifugation the 
supernatant was loaded onto an Ni-affinity column previously equilibrated with 20 mM 
sodium phosphate at pH 8, 150 mM NaCl, 0.1 mM DTT and 10 mM imidazole. The 
concentration of imidazole was increased stepwise, first to 80 mM to remove no specifically 
bound proteins, and then to 500 mM to elute the enzyme. Soluble TgCGL eluted between 200 
and 250 mM imidazole. After addition of 100 µM PLP, the fraction containing TgCGL were 
concentrated and washed with 20 mM sodium phosphate buffer pH 8, 0.1 mM DTT using 
Vivaspin concentrators (Sartorius) to remove imidazole and unbound PLP. 
The extinction coefficient was used to calculate the monomer concentration of the purified 
protein (ε280nm = 30745 M−1 cm−1; http://web.expasy.org/protparam/). The PLP content of the 
holo-enzyme was determined by addition of 0.1 M NaOH and using ε388nm = 6600 M−1 cm−1 as 
described [96]. 
The S77E, S77A and N360S TgCGL variants was produced by site specific mutagenesis on 
the pET21a-TgCGL construct using the QuikChange® site-directed mutagenesis kit (Agilent 
Technologies). The mutated sequences were confirmed by DNA sequence analysis. 
Expression and purification of the S77E, S77A and N360S variants were performed as 
described for wild-type TgCGL. The yield from a one-liter purification was approximately 20 
mg for all enzyme variants. 
 
2.2 Size exclusion chromatography (SEC) 
Gel filtration chromatography (Superdex 200 HR 10⁄300 GL) was used to analyze the 
oligomeric state of TgCGL. Chromatography was performed using 50 mM sodium phosphate 
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buffer pH 8.5, 150 mM NaCl, 0.1 mM DTT. The calibration curve was obtained as described 
[46]. In order to investigate the quaternary structure stability, the protein was incubated with 
increased concentration of urea (0 - 5.5 M) for 1 h, and loaded on the gel filtration column 
previously equilibrated with the specific urea concentration. The percentage of tetrameric 
protein was measured by integration of the area under the curve (absorbance at 280 nm) using 
the Evaluation module of Unicorn 7.0.2 software. The data were fit by sigmoidal curves and 
the concentration of urea at which 50% of TgCGL is tetrameric (Cm) was determined. 
 
2.3 Apo-proteins preparation 
Apo-proteins were obtained following the protocol in [94, 97]. The apo-proteins showed no 
absorption peak at 421 nm and no residual activity. The equilibrium dissociation constant for 
PLP (KDPLP) was obtained by measuring the fluorescence emission at 330 nm upon excitation 
at 280 nm in the presence of PLP ranging from 0.05 to 40 µM at 25 °C in 50 mM Bis-Tris 
propane pH 8 at apo-proteins concentration of 1 µM. The values of fluorescence intensity at 
330 nm were plotted as a function of PLP concentration and fit to a non-linear binding 
equation to obtain the dissociation constant KD. 
 
2.4 Limited proteolysis 
Fifty micrograms of holo- and apo-TgCGL were digested with trypsin (1:200 w/w) in 50 mM 
Tris-HCl pH 7.5 at 25 °C. At various time intervals (0, 1, 5, 10, 20, 40, 60 and 120 min), 8µl 
aliquots were taken for electrophoretic analysis. The digestion reaction was ended by boiling 
the sample for 5 min and adding reducing Laemmli buffer. After staining the gel with 
Coomassie blue, the bands intensities analysis was performed as described [98]. 
 
2.5 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) experiments were conducted using a TA Instrument 
Nano-DSC (New Castle, Delaware, USA). TgCGL samples of 50-100 µM were dissolved in 
in 20 mM sodium phosphate pH 8, and were heated from 10 °C to 120 °C at a scan rate of 
1°C/min. All the samples were degassed prior to analysis. 
 
2.6 Enzyme activity assays 
Enzyme activity was determined using a Jasco-V560 UV-Vis spectrophotometer (Easton, 
Maryland, USA) via two spectrophotometric assays: the reaction of 5,5′-dithiobis-(2-
nitrobenzoic acid) (DTNB) with the free thiol of the product (ε412 = 13600 M−1 s−1), and by 
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monitoring the pyruvate formation with the coupling enzyme NADH-dependent lactate 
dehydrogenase (LDH) (ε340 = 6200 M−1 cm−1), as described [49]. All enzymatic assays were 
carried out at 37°C in 50 MOPS, bicine, proline (MBP) buffer pH 9 in the presence of 20 µM 
PLP. Reactions were initiated by the addition of the enzyme at a final concentration of  1, 5 or 
10 µM, depending on the activity of the enzyme variant. A background reading was recorded 
before initiation of the reaction by the addition of TgCGL. 
Data were fitted to the Michaelis–Menten equation to obtain values of kcat and Km . For site-
directed variants for which saturation was not observed, kcat/Km values were obtained by 
linear regression, based on the assumption that Km ≫ [substrate]. The L-cys hydrolysis data 
were fitted to equation (5), which modifies the Michaelis-Menten equation taking into account 
the Ki term for substrate inhibition by L-cysteine [99]: 
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where E is the total enzyme concentration, kcat the rate constant, S the substrate concentration, 
Km the apparent Michaelis-Menten constant and Ki the dissociation constant. 
To evaluate the effect of temperature on α,γ-lyase activity, the enzyme was incubated for 10 
min at temperatures between 20 °C and 90 °C, cooled on ice for 5 min, and the residual 
enzymatic activity was determined as described above. 
 
2.7 Inhibition assays 
The inhibitory activity of L-cys was evaluated through LDH assay and was expressed as the 
inhibitor concentration required for 50% inhibition of the α,β-eliminase activity (IC50). The 
IC50 value was measured by a plot of percent activity versus log of L-cys concentration. 
The kinetic parameters of α,β-eliminase inhibition by L-cys were evaluated by the 
Lineweaver–Burk plots and its secondary plots. The double-reciprocal plots were constructed 
with enzyme reaction initial velocity (V) versus substrate (S) concentration in the absence 
(control) or presence of L-cys at different concentrations. The type of inhibition, Km and Vmax 
values were determined from the plots. Slopes and Y-intercepts of these reciprocal plots were 
also replotted against the inhibitor concentration, respectively [100]. Data analysis was 
performed by OriginLab software. 
Inactivation of TgCGL by DL-proparglyglycine (PAG) was evaluated by reacting 5 mM L-cth 
with TgCGL (2 µM), pre-incubated with different concentration of the inhibitor for 15 min at 
room temperature. Reactions were monitor through DTNB assay. Residual activity, remaining 
after 15 min incubation, was plotted against the relative concentration of PAG. 
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2.8 Spectroscopic measurement 
Absorption measurements were performed on a Jasco-V560 UV-Vis spectrophotometer 
(Easton, Maryland, USA) in a buffer solution containing 50 MBP buffer pH 9, at protein 
concentration of 12 µM. 
In order to evaluate the the equilibrium dissociation constant for TgCGL-L-cys complex 
formation (Kapp), absorption spectra of TgCGL were recorded upon addition of different L-
cysteine concentrations: 0, 0.04, 0.1, 0.15, 0.16, 0.2, 0.3, 0.4, 0.5, 0.8, 1, 2, and 3 mM. The 
plots of the absorbance changes at 335 and 421 nm against the L-cys concentration could be 
fitted to a hyperbolic relationship such as equation (6) : 
∆ 
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  (6) 
where ∆A and ∆Amax are the absorption changes at given and infinite L-cys concentrations 
respectively, and Kapp the equilibrium dissociation constant for TgCGL-L-cys complex 
formation. 
 
2.9 Statistical analysis 
Each experiment was performed at least in triplicate and reported values are representative of 
two or more independent determinations using different batches of protein that were purified 
separately. Data were analyzed using Origin 8.0 (OriginLab Corporation, Northampton, MA) 
and expressed as mean ± standard error. 
 
2.10 Thin layer chromatography 
Amino acid standards (1 mg/mL) were prepared in 20 mM sodium phosphate buffer, pH 8.0. 
These solutions were spotted, 1 µL at a time, on chromatographic plates, comprised of a 0.1-
mm thick layer of silica gel on an aluminum support, and developed with a mobile phase of n-
propanol/water (70:30, v/v), for a distance of 13 cm. TLC plates were subsequently dried, 
sprayed with a solution of 2 mg/mL ninhydrin in ethanol and dried, prior to heating for 5 min 
at 100°C. 
 
2.11 Molecular modelling studies 
The crystal structure of Methionine γ-lyase from Citrobacter Freundii in its internal aldimine 
form (PDB ID code 5E4Z) and human cystathionase (Cystathionine γ-lyase) in complex with 
PAG (PDB ID code 3COG) were used as a starting point to generate the model of the wt, 
N360S and S77E TgCGL enzyme, using the “homology modeling” tool of PyMod 2.0, 
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followed by energy minimization with the BIOPOLYMER package from InsightII (V.2000, 
MSI, Los Angeles), as already described [53, 101]. 
The Dundee PRODRG2 Server [54] was used to build the energy minimized three-
dimensional structures of the PLP-Cystathionine and PLP-PAG external aldimines complexes, 
which were then docked into the active site of wt form of TgCGL, using the template-based 
molecular docking approach of Molegro Virtual Docker (MVD) software (CLCbio®). 
Flexible torsions of the external aldimines were automatically detected by MVD, and 
manually checked for consistency. A search space of 15 Å radius, centered on the active site 
cavity, was used for docking. The PLP in its internal aldimine form, as found in 3COG, was 
taken as pharmacophoric group for template-based docking. In the latter, if an atom of the 
ligand matches a group definition, it is rewarded by using a weighted score that depends on its 
distance to the group centers. The grid-based MolDock score with a grid resolution of 0.30 Å 
was used as scoring function and MolDock SE was used as docking algorithm [55]. For each 
ligand, ten runs were defined. Similar poses (RMSD ≤ 1.0 Å) were clustered, and the best 
scoring one was taken as representative. Other docking parameters were fixed at their default 
values. After docking, energy optimization of hydrogen bonds was performed. 
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nm led to a single emission peak with a maximum at ~500 nm, thus further confirming the 
assignment of the 421 absorbance band to the ketoenamine tautomer (data not shown). 
The emission spectrum of the apo-TgCGL following excitation at 280 nm had an emission 
band at 331 nm with an intensity approximately 1.5-fold greater than that of holoenzyme, as a 
consequence of the quenching of the emission fluorescence due to the bound PLP in the holo-
form (Figure 25B). The dissociation constant (KD) for the binding of PLP to TgCGL was 
measured by titrating apo-TgCGL with increasing amounts of PLP and following the 
fluorescence signal upon excitation at 280 nm. This analysis yielded a KD value for the 
TgCGL–PLP complex of 0.17 ± 0.04 µM. 
 
Figure 25. Spectral properties of TgCGL. (A) Absorption spectrum of purified TgCGL recorded 
on a solution containing 12 µM protein in 50 mM MBP buffer pH 9. (B) Fluorescence spectra 
(excitation was at 280 nm) of holo-TgCGL (dotted line) and apo-TgCGL (solid line) in 20 mM 
Bis-Tris-propane pH 8.3, at a concentration of 1 µM. 
 
Limited trypsin proteolysis experiments on the holo- and apo-forms of TgCGL provided 
evidence for a protective effect of PLP. After 10 minutes of reaction, the 70% of apo-protein 
was already digested by protease; by contrast, after the same time, a 40% decrease in the 46 
kDa-band intensity of holo-protein was observed. In the holo-state TgCGL was stable to 
proteolysis for more than 120 min. (Figures 26A and 26B).  
Moreover, the holo-enzyme exhibited a higher thermal stability (Tm of about 71°C at pH 8.0) 
compared to the apo-protein (Tm value at about 55 °C) as observed by DSC (Figures 26C and 
26D).  
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min, respectively. The intensity of the untreated with trypsin TgCGL band (lane 0 min) was 
assumed as 100%. The arrow indicates the untreated 46 kDa band. Lane M represents a molecular 
mass marker. (C) and (D) Representative DSC thermograms of apo
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The L-cth hydrolysis activity of the TgCGL was measured with both the DTNB and LDH 
assays. Indeed, the DTNB-based assay does not distinguish between the products of L-cth 
hydrolysis, which are L-homocysteine (L-hcys) and L-cys for the β- and γ-elimination 
reactions, respectively. Therefore, we employed also the LDH assay to monitor the formation 
of L-pyruvate product by specific L-cth α,β-elimination. Determination of L-cth hydrolysis 
via DTNB assay at pH 9 resulted in kcat and Km values of 2.0 ± 0.1 s-1 and 0.9 ± 0.1 mM, 
respectively, whereas a negligible activity was detected via LDH-coupled assay (the enzyme 
specific activity was < 0.4% compared to that measured by DTNB assay). Thus, TgCGL 
resulted highly specific for α,γ-elimination of L-cth, like in T. cruzi [92] and in human [102], 
[103], where L-cth is split almost exclusively in a CGL-specific manner, whereas the yeast 
enzyme harbors pronounced CBL activity [104]. 
Besides its role in the conversion of L-cth into L-cys, we found that TgCGL can also utilize 
djenkolic acid (Appendix, Figure A3), and amino-ethyl-L-cysteine, to a lesser extent (kcat 
0.037 ± 0.001 s-1 and Km 1.3 ± 0.1 mM), via an α,β-elimination reaction (Table 4). L-cys 
served as a very poor substrate with a maximum velocity only 1 % of the value with the 
natural substrate L-cth. Substrate inhibition was also observed (kcat 0.024 ± 0.001 s-1, Km 0.7 ± 
0.2 mM and Ki 0.17 ± 0.02 mM). 
 
Table 4. Steady-state kinetic parameters of TgCGL variants a at pH 9 and 37°C 
 Assay kcat b(s-1) Km b(mM) kcat/ Km (mM-1s-1) 
Hydrolysis  of L-cystathionine    
wt DTNB 2.0 ± 0.1 0.9 ± 0.1 2.2 ± 0.4 
N360S DTNB 0.24 ± 0.02 6.1 ± 1.2 0.04 ± 0.01 
 
LDH 0.08 ± 0.01 1.1 ± 0.1 0.07 ± 0.02 
S77A DTNB 0.7 ± 0.1 2.4 ± 0.3 0.29 ± 0.08 
S77E LDH/DTNB n.d.b n.d. b - 
 
   
Hydrolysis  of djenkolic acid    
wt LDH 0.24
 
± 0.01 0.51
 
± 0.01 0.47 ± 0.03 
N360S LDH 0.19 
 
± 0.01 0.86
 
± 0.03 0.22 ± 0.02 
S77E LDH n.s.c n.s. c 0.0022 ± 0.0006 
S77A LDH 0.22 ± 0.02 1.5 ± 0.2 0.15 ± 0.03 
a TgCGL at 1, 5 or 10 µM was used, depending on the activity of the specific enzyme variant.  
b not detected. 
c The notation n.s. indicates that S77E does not display saturation kinetics within the 
solubility limit of the djenkolic acid substrate, such that kcat/Km was determined via linear 
regression with the assumption that Km ≫ [djenkolic acid].  
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Moreover, L-cys showed an inhibitory effect when assessed via LDH assay on djenkolic acid 
β-elimination by TgCGL. Plot of percentage inhibition versus log of L-cys concentration 
resulted in an IC50 value of 0.27 ± 0.05 mM (Figure 28A). We next estimated the Ki for L-cys 
by measuring the dependence of the initial velocity on djenkolic acid concentration (from 0.1 
to 12 mM). (Appendix, Figure A4). The data were analyzed in double reciprocal (Lineweaver-
Burk) plot and were interpolated by four straight lines resulting in a common intersection 
point in the second quadrant characteristic of mixed-type inhibition (Figure 28B). kcat value 
decreases from 0.24 (no-inhibitor) to 0.12 s-1 and Km value increases from 0.53 to 1.19 mM 
with increasing concentration of L-cys. Secondary plots of the slope and Y-intercept values, 
obtained from each line in the primary Lineweaver-Burk plot versus L-cys concentrations 
(Figure 28C), allowed extrapolation of enzyme inhibitor dissociation constants Ki (the 
enzyme inhibitor (EI) constant) and Ki’ (the enzyme substrate complex (ESI) constant), 
respectively. The smaller value of Ki (160 ± 30 µM) than Ki′ (370 ± 50 µM) indicates that L-
cys binds with higher affinity to the free enzyme in comparison with the enzyme-substrate 
complex. 
The availability of large amounts of the recombinant protein allowed us to analyze directly 
the interaction between TgCGL and L-cys by collecting absorption spectra. Upon addition of 
L-cys to TgCGL we observed an immediate decrease in the absorption at 421 nm (Figure 
28D). Such decrease was concomitant with the appearance of a new maximum at 335 nm, 
which is characteristic of a thiazolidine adduct between L-cys and the PLP cofactor [105]. 
Indeed, it is well known that L-cys, in addition to the general ability to work as substrate for 
most CGL enzymes [102, 104], may bind to the aldehyde group PLP cofactor to form 
thiazolidine [106]. The recording of the spectra obtained for increasing concentrations of L-
cys (Figure 28D) showed an isosbestic point at 370 nm, indicating the presence of only two 
species in the mixture, free TgCGL and L-cys-complexed enzyme. The plots of the 
absorbance changes at 335 and 421 nm against the L-cys concentration (Figure 28D inset), 
fitted to equation (6), yielded Kapp values of 306 ± 41 µM and 273 ± 52 µM, respectively. The 
average value for Kapp (290 µM) is consistent with those determined from the enzyme-
inactivation data. 
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Figure 28. Inhibition of TgCGL β-eliminase activity by L-cys. (A) Representative profile of IC50 
determination. The enzymatic activity of TgCGL was related to the activity in the absence of 
inhibitor (100%). The in vitro  inhibition of enzyme by L-cys was performed in the presence of 6 
mM djenkolic acid substrate via LDH assay. (B) Lineweaver-Burk plot analysis of the kinetics of 
TgCGL inhibition exerted by L-cys. (C) Slope and Y-intercept values from primary Lineweaver-
Burk plot (panel B) versus L-cys concentrations; Ki, and Ki’ were obtained as the absolute values 
of the concentration-axis intercepts of slope and Y-intercept plots, respectively. (D) Absorption 
spectra of 12 µM TgCGL upon addition of the following L-cys concentrations: 0, 0.04, 0.1, 0.15, 
0.16, 0.2, 0.3, 0.4, 0.5, 0.8, 1, 2, and 3 mM. Inset. Absorbance changes at 335 (solid circle) and 
421 nm (open square) plotted against L-cys concentration. 
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We also analyzed the behavior of TgCGL in the presence of PAG as it is the most widely used 
in vivo inhibitor of H2S production by human CGL. The irreversible inactivation of human 
CGL by PAG has been well described [102, 103, 107]. We found that PAG inhibited also 
TgCGL. Because of the rapidity of the inactivation (PAG inactivated the enzyme faster than 
the manual mixing time for the samples), we measured the residual activity after a 15-min 
incubation of TgCGL with increasing concentrations of PAG (Figure 29). The very fast 
inactivation of TgCGL by PAG was not surprising, since the same behaviour was observed 
for human CGL [102, 103]. Notably, enzymatic activity of TgCGL could not be recovered by 
extensive dialysis, therefore confirming the irreversible inhibition. 
 
Figure 29. Residual activity of TgCGL after incubation with PAG. The inhibition of enzyme by 
PAG was measured in the presence of saturating concentrations of L-cth (5 mM) via the DTNB 
assay following pre-incubation with different concentration of the inhibitor for 15 min at room 
temperature. 
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3.4 Molecular modelling 
We modelled the external aldimine of the wt enzyme in complex with L-cth and PAG, starting 
from the homology-modelled tetramer structure of TgCGL (residues 35-417) in its internal 
aldimine state. To this end, we used the crystal structures of methionine γ-lyase from 
Citrobacter Freundii (PDB ID code 5E4Z; % identity ≈ 44.2) and human CGL in complex 
with PAG (PDB ID code 3COG; % identity ≈ 41.3) as structural templates. 
The predicted binding mode of L-cth in wt TgOAT is shown in Figure 30A. With the α-amino 
group of the substrate covalently bound to PLP, the carboxylate group of L-cth is well 
positioned to form an ion-pair with Arg395 and hydrogen-bonds with Asn180 and the N main-
chain atom of Asn360. These interactions are also well conserved in the crystal structure of 
human CGL (residues Arg375, Asn161, Ser340; PDB ID code 3COG), where a nitrate ion 
occupies approximately the same position of the carboxylate group of L-cth in the predicted 
docked model. Moreover, and similarly to what observed in the crystal structure of human 
CGL, the ζ-amino and ζ-carboxyl groups of L-cth are predicted to share with the carboxyl and 
amino moieties of PAG the same interactions with two arginine residues (i.e., Arg80 and 
Arg138 of TgCGL and Arg62 and Arg119 in human CGL) and a glutamic acid (i.e., Glu359 
of TgCGL and Glu339 in human CGL). Another interaction involving the ζ-amino moiety is 
represented by a water-bridged hydrogen bond with the hydroxyl group of Tyr71. The latter 
residue has no homologous counterpart in the human CGL, and its water-bridged hydrogen 
bond interaction with L-cth is replaced by the carboxyl group of human CGL Glu59.  
When comparing the modelled position of PLP- L-cth and its interacting residues into the 
active site of TgCGL with the corresponding residues in human and yeast CGL, one striking 
differences is the replacement of the conserved residues of Ser334/Ser340 and Glu48/Glu59 
(numbering refers to the yeast and human CGL, respectively) with Asn360 and Ser77 in 
TgCGL (Figure 30A). Therefore, we decided to exchange these two positions in TgCGL with 
the corresponding residues of human and yeast enzymes to test their effect on substrate and 
reaction specificity. 
We also modelled wt form of TgCGL in complex with PAG and the modelling reveals that 
this covalent inhibitor could act as already observed in the human enzyme (covalent bond 
with Tyr133), since the residues interacting with the inhibitor are all well conserved between 
human CGL and TgCGL (Figure 30B). 
 
 Figure
TgCGL is shown as green sticks, and 
The external aldimine is shown as pink sticks. Residues described in text are labeled in single
Potential favorable interactions are depicted as yellow. (B) The covalent bond between
sticks) and Tyr133 of TgCGL (cyan sticks) is shown superposed with the corresponding residues of 
human CGL (PDB: 3COG; gray sticks).
 
 30. Modelling of the external aldimine of wt 
 
superposed to human CGL (PDB:3COG; transparent gray sticks).
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TgCGL in complex with L-cth (A) and PAG (B)
-letter code. 
 PAG (purple 
. (A) 
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3.5 N360S variant 
The absorbance spectrum of N360S showed a major peak at 421 nm, as the wt protein, and a 
minor peak at ~500 nm, which is not present in wt enzyme but it has been already seen in the 
human CGL protein preparations [102, 103, 108]. This 500 nm absorption band disappeared 
by reconstitution of TgCGL N360S with PLP following the generation of apo-protein (Figure 
31), therefore it is tentative to speculate that it could be ascribed to a quinonoid species 
formed by a bound amino acid that co-purifies with TgCGL. As for wt enzyme, the N360S 
variant binds ~1 mol of PLP/mol of monomer. 
 
Figure 31. UV–visible absorption spectra of TgCGL N360S variant. Spectra are for native enzyme 
after purification (solid line), apo-protein (dashed line), and reconstituted holoenzyme (dotted 
line). 
 
Substitution of N360 with Ser led to a ~56-fold decrease in catalytic efficiency for L-cth 
hydrolysis when analyzed via DTNB assay compared to the wt enzyme, and the change was 
influenced by matched ~10-fold decrease in kcat and ~7-fold increase in Km. Most importantly, 
α,β-cleavage of L-cth estimated via LDH-based assay was significantly increased (from 
negligible activity < 0.4% of that detected by DTNB assay in the wt enzyme to ~ 33% in 
N360S variant), and the Km for β-elimination of L-cth was reduced by ~ 6-fold compared to 
the one obtained by DTNB analysis (Table 4), suggesting that the binding of L-cth in a 
conformation suitable for α,β-elimination is favored. The α,β-hydrolysis of L-cth was also 
assayed at different pH and the optimum was at 9 (data not shown). 
Qualitative comparison of the reaction products with L-cth, L-hcys and L-cys standards via 
thin layer chromatography (TLC) analysis confirmed the production of both L-hcys and L-cys 
when L-cth was used as substrate for the N360S enzyme, thus confirming the ability of this 
variant to catalyze both α,β and α,γ-elimination toward L-cth (Figure 32). 
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Figure 32. Product analysis of the amino acid products of L-cth hydrolysis by wt and N360S 
variants TgCGL. Reaction products and amino acid standards were separated by TLC and 
derivatized with ninhydrin. Lane 1-3, amino acids standards. Lane 1: 1 mg/mL L-cth; lane 2: 1 
mg/mL L-cys; lane 3: 1 mg/mL L-hcys; lane 4: 5 mM L-cth + 100 µM wt TgCGL; lane 5: 5 mM 
L-cth + 100 µM N360S TgCGL; lane 6: 5 mM L-cth + 10 µM cystathionine β-lyase from 
Corynebacterium diphtheriae which catalyzes the β-elimination of L-cth to generate ammonia, 
pyruvate, and homocysteine. 
 
The replacement of Asn360 by Ser had no significant effect on α,β-elimination activity 
towards L-cys and djenkolic acid, since for these substrates the enzyme variant showed near 
wt kinetic parameters (Table 4). L-cys also inhibited TgCGL N360S with an IC50 of 0.43 ± 
0.02 mM (Figure 33A). Accordingly, the average Kapp for TgCGL N360S-L-cys complex 
formation determined from spectral analyses was 333 µM (Kapp of 335 ± 15 µM at 335 nm, 
Kapp of 331 ± 20 µM at 421 nm) (Figure 33B). 
 
Figure 33. Inhibition profiles of TgCGL N360S variant by L-cys. (A) Representative curve for 
IC50 determination. The enzymatic activity of TgCGL N360S variant was related to the activity in 
the absence of inhibitor (100%). The in vitro inhibition of enzyme by L-cys was performed in the 
presence of djenkolic acid substrate via LDH assay. (B) Absorbance changes at 335 (solid circle) 
and 421 nm (open square) plotted against L-cys concentration. 
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The modelled N360S enzyme in its external aldimine form in complex with the L-cth 
substrate bound in opposite orientation (in agreement with the distinct α,β versus α,γ-
elimination reaction specificity requirements) allowed us to rationalize the TgCGL N360S 
behavior. Notably, in the presence of N360, the binding of L-cth in a conformation suitable 
for α,β-elimination is partially hindered (see Figure 34A and compare with the orientation of 
L-cth shown in Figure 30A), due to the slight steric clash with the bulky S atom in position γ 
of L-cth. On the contrary, the N360S mutant is predicted to accommodate well both binding 
modes of L-cth (Figure 34B). Accordingly, the sulfur atom of the L-cth substrate was 
proposed to be an important determinant of the orientation of substrate binding and, therefore, 
reaction specificity in yeast CGL [95].  
 
 
Figure 34. Modelling of the external aldimine of PLP-L-cth in complex with wild-type TgCGL (A) 
and N360S mutant TgCGL (B). The external aldimine of PLP-L-cth is shown as pink sticks, and 
the surrounding residues as green sticks. Residues described in text are labeled in single-letter 
code. The Van der Waals radius of the Sγ atom of L-cth is shown as yellow dots. The Van der 
Waals radii of Nγ N360 and Oβ S360 are shown as blue and red dots, respectively. 
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3.6 S77E variant 
We found no difference in the absorption spectrum of S77E and in the stoichiometry of PLP-
bound (~1 mol of PLP per monomer) compared to wt enzyme. 
Notably, replacement of Ser77 by glutamate completely abolished activity toward L-cth. We 
made different attempts to determine enzymatic activity, including long incubation times, and 
increased substrate and enzyme concentrations, but none α,γ and α,β-elimination activities 
were detected. 
Also the α,β-elimination activity of S77E variant was also seriously compromised. Only by 
increasing enzyme concentration in the assay we were able to determine the steady-state 
kinetic parameters of S77E towards djenkolic acid and amino-ethyl-L-cysteine, which 
however showed a net decrease of S77E enzyme catalytic efficiency (by 214- and 90-fold for 
djenkolic acid and amino-ethyl-L-cysteine, respectively) compared to wt enzyme. 
The potential of the active-site residue S77 to influence L-cth hydrolysis was also explored 
via characterization of the S77A substitution. However, the near wt kinetic parameters for 
S77A variant did not support a direct and key role for this residue in catalysis (Table 4). 
When testing the L-cys inhibitory effect on djenkolic acid β-elimination by TgCGL S77E, we 
found a IC50 value of 0.55 ± 0.09 mM (Figure 35A). Moreover, a Kapp of 797 µM for TgCGL 
S77E-L-cys complex formation was determined from spectral analyses (Kapp of 677 ± 180 µM 
at 335 nm, Kapp of 874 ± 87 µM at 421 nm) (Figure 35B). 
 
Figure 35. Inhibition profiles of TgCGL S77E variant by L-cys. (A) Representative curve for IC50 
determination. The enzymatic activity of TgCGL S77E variant was related to the activity in the 
absence of inhibitor (100%). The in vitro inhibition of enzyme by L-cys was performed in the 
presence of djenkolic acid substrate via LDH assay. (B) Absorbance changes at 335 (solid circle) 
and 421 nm (open square) plotted against L-cys concentration. 
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Due to the presence of Tyr71, which is missing in human CGL, in the modelled S77E mutant 
the side-chain of Glu77 is unable to occupy the same position of the homologous Glu59 of 
human CGL, since this would cause a steric clash with Tyr71 (Figure 36). Instead, the side-
chain of Glu77 is forced to occupy the same cleft of L-cth, possibly interfering with its 
binding. The overall effect of the S77E mutation could affect also the stability of the 
quaternary structure of the enzyme, since this residue is placed on a loop making close 
contacts with two other monomers of TgCGL (Figure 36, inset window). 
 
 
 
Figure 36. Modelling of the external aldimine of wild-type (A) and the S77E mutant (B) of 
TgCGL in complex with L-cystathionine. The external aldimines are shown as pink sticks. 
Residues described in text are labelled in single-letter code. Potential favourable and unfavourable 
interactions are depicted as yellow (A) and red (B) dashes, respectively. The position of the loop 
hosting E77 relatively to the other chains (A=yellow; B=pink; C=cyan; D=blue) of the quaternary 
structure is shown in the inset of panel (B). 
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The effect of mutation on structure stability of TgCGL was probed by analyzing the thermal 
stability of the protein both in apo- and holo-state by DSC. The holo-S77E variant showed a 
Tm value of about 66°C at pH 8.0, therefore indicating that the single amino acid substitution 
is associated with a 5 °C decrease in the protein thermal stability (Figure 37A). In contrast, 
the thermogram of apo-S77E variant displayed a profile identical to that of apo-wt protein 
with Tm value of about 55 °C (data not shown). Moreover, we evaluated the quaternary 
structure stability of wt and S77E enzyme variants by chemical denaturation with urea. The 
loss of TgCGL quaternary structure was measured by monitoring changes in protein size on a 
gel filtration column as a function of changes in the concentration of urea. Figure 37B shows 
representative unfolding curves for the wt and S77E isoforms in urea. The data were fitted by 
sigmoidal dose-response curves with variable slope. The midpoint transition values (Cm) 
between tetramer/nontetramer were 2.9 ± 0.1 M and 2.4 ± 0.2 M for the wt and S77E variants, 
respectively. 
 
Figure 37. Effect of S77E mutation on thermal stability and quaternary structure of TgCGL. (A) 
Representative DSC thermograms of holo-S77E (solid line) and holo-wt (dashed line), 
respectively after baseline-correction. (B) Plot of percent tetrameric (% T) TgCGL wt (open 
square) and S77E (solid circle) as a function of the urea concentration. Inset: chromatograms of  
wt (solid line) and S77E (dotted line) TgCGL at 2.5 M urea.  
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4. DISCUSSION 
 
The present work shows that T. gondii possesses a functional CGL which specifically 
catalyzes the cleavage at the CγS bond of L-cth, producing L-cys, α-ketobutyrate and 
ammonia. This finding likely implies that the reverse transsulfuration pathway is operative in 
the parasite. Furthermore, TgCGL was shown to convert L-cys orders of magnitudes more 
slowly than the natural substrate L-cth. Cysteine is an inhibitor of TgCGL, which likely 
suggests that, at a physiological cysteine:cystathionine ratio, the parasitic enzyme might be 
inhibited. This would permit tight regulation of cysteine intracellular levels, preventing its 
intracellular accumulation. 
The enzymes of the γ-subfamily of fold-type I, especially CGS, CBL and CGL, represent and 
ideal model for the investigation of the structure-function relationship in terms of substrate 
and reaction specificity [109]. Some residues that are proposed to participate in substrate 
binding and catalysis are well conserved among these enzymes, even though these enzymes 
catalyze mechanistically distinct reactions. 
Due to the high degree of similarity between TgCGL and human CGL (e.g. 40% sequence 
identity) it constitutes a tremendous task to design inhibitors that can distinguish between the 
nearly superimposable active sites of CGL. However, by structure-guided homology 
modelling and mutational analysis, we identified the residues Asn360 and Ser77 of TgCGL as 
important for the reaction and substrate specificity of the parasitic enzyme. 
Mutation N360 to the corresponding residue in human (Ser) was found to influence the 
reaction preference of the parasitic enzyme, such that the N360S mutant harbors a significant 
L-cth β-lyase activity. It is an intriguing question what determines the reaction specificity for 
the catalysis of α,γ- versus α,β-elimination of the same substrate L-cth. 
It is known that both CBL and CGL catalyze the hydrolysis of L-cth, but split the substrate at 
β- and γ- positions, producing homocysteine and cysteine, respectively. The pseudo-
symmetric L-cth substrate, containing the equivalent of two Cα atoms, binds in opposite 
orientations in the active sites of CBL and CGL to allow β- versus γ-elimination [87]. 
Messerschmidt et al [95] suggested that the orientation of the L-cth in yCGL is partially due 
to its sulfur atom. Indeed, as demonstrated by our molecular modelling analysis, the 
substituted Ser allows a better accommodation of L-cth for the β-cleavage than wt, in which 
the Asn residue create steric obstruction. 
Furthermore, Messerschmidt et al [95, 110] predicted that the reaction specificity of the 
enzyme for the α,γ- elimination versus α,β- elimination would depend on a pair of residues 
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located in the substrate entrance region. These residues are very conserved among CGLs and 
corresponds to a pair of glutamate residues (E48-E333 in yeast CGL and E59-E339 in human 
CGL). CBL enzymes generally possess aromatic residues in those positions, that lead to more 
hydrophobicity in the active site. Replacement of C-term Glu in yeast and human CGL 
indicated that this residue plays a unique role in the reaction specificity. In particular, the 
replacement of Glu333 in yeast CGL indicated that this residue interacts with distal amino 
moiety of L-cth and plays a unique role in the substrate binding [104]. Moreover, in human 
CGL, substitution of Glu339 with a hydrophobic residue increased the α,β elimination 
reaction toward L-cys [111]. On the other hand, mutational analysis of Glu48 in yeast CGL 
suggested a role into active site architecture or substrate positioning, therefore subtly and not 
directly influencing reaction specificity. Replacement of the corresponding D45 of CGS from 
E.coli with alanine or asparagine also results in only 2–9-fold changes in kinetic parameters, 
but enables a minor transamination activity, suggesting a subtle role into active site 
architecture or substrate positioning [112]. Notably, the mutation S77E in TgCGL completely 
abolished the activity toward L-cth, probably due to a complete rearrangement of the active 
site that prevents the binding of L-cth. However, the analysis on S77A mutant showed that 
this is not a catalytic residue. Molecular modelling results demonstrated that the presence of 
Tyr71, which has no homolog in human CGL, forces the Glu77 of the S77E variant to occupy 
the same cleft of L-cth This finding reinforces the importance of the structural contest of 
parasitic and human enzymes in defining the architecture of the active sites. Moreover, the 
mutation has a significant impact on the structural stability of TgCGL, as demonstrated by 
DSC and SEC analysis, according to the fact that this residue is placed on a loop in close 
contact with two other monomers. 
These results provide support for the theory, proposed by Clausen [113], that the 
conformation and orientation of substrate(s) within the active site as well as the degree of 
freedom of rotation about the Cα–Cβ bond of the substrate covalently bound to the cofactor 
are determinants of reaction specificity among the enzymes of the γ-subfamily. 
Moreover, despite the high similarity of CGL enzymes among different organisms, there are 
subtle differences in active site architecture which have important implications for enzyme 
functionality. We must await data on the three-dimensional structure of TgCGL for a 
thorough interpretation of these differences.. 
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 General conclusions 
 
In this work we investigated the possible use of TgOAT and TgCGL as anti-toxoplasmosis 
drug targets and we contributed to gain knowledge about two metabolic pathways that are still 
poorly explored in T. gondii. However, our in vitro and in silico analysis could be considered 
only a first step toward the structure-based selective drug design development. First of all, the 
respective PLP-dependent host enzymes as well as the likely broad specificity of target 
inhibition have to be taken into account. In this regard, the effect of known inhibitors has to 
be investigated in order to provide new insights into the inhibition mechanism of the enzyme. 
Moreover, a virtual screening approach will lead to the rational design of more selective 
inhibitors that, subsequently, can be chemically synthesized and in vitro tested. Finally, future 
in vivo studies will be necessary to examine in depth the effective roles of these enzymes in 
the parasitic cell processes and infection. 
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 Appendix 
 
Figure A1 
Figure A1. GOX-coupled assay calibration curve. The straight line obtained is y = -0.0874 + 
0.00588x, in presence of L-glutamate, ranging from 10 to 500 µM, α-KG 5 mM, PLP 0.05 mM and 
phosphoric acid 14 mM. 
 
Figure A2 
Figure A2. Michaelis – Menten profiles of TgOAT. Representative curve of TgOAT activity 
towards L-orn (A) and GABA (B) in the presence of 5 mM α-KG, 50 µM PLP in 50 mM Hepes pH 
8 at 37 °C. 
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Figure A3 
Figure A3. Michaelis – Menten profiles of TgCGL wt. Representative curve of TgCGL activity 
towards L-cth (A) and djencolic acid (B) at 37°C in 50 MBP buffer pH 9 in the presence of 20 µM 
PLP. 
 
Figure A4 
Figure A4. Inhibitory effect of L-cys on TgCGL activity. The initial velocity of enzymatic 
reaction was measured as a function of djencolic acid concentration at 0 (○), 100 (◄), 300 (□) and 
500 (♦) µM of L-cys. 
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